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Glucocorticoid receptor (GR) 
is a corticosteroid-controlled 
transcription factor important in 
the mediation of anti-inflammatory 
effects. In addition to corticosteroids 
the action of GR can also be regulated 
by post-translational modifications. 
This study proves by transcriptome 
and cistrome analyses that small 
ubiquitin-related modifier (SUMO) 
regulates GR action in basal and cell 
stress conditions. The novel results 
represented will be valuable for 
future targeting of GR in health and 
disease.
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ABSTRACT 
 
Glucocorticoids regulate many vital biological processes by influencing gene expression via 
the glucocorticoid receptor (GR). Glucocorticoids exert strong anti-inflammatory and -
proliferative effects; for this reason they are extensively used not only for the treatment of 
inflammatory diseases but also in hematological malignancies. Binding of the GR to 
chromatin influences gene expression by modifying the activity of other transcription 
factors (TFs) and coregulators as well as by altering chromatin structure. Genome-wide 
binding and gene expression data have revealed that GR largely binds to distal enhancers, 
thus regulating transcription via long-range interactions. In addition to glucocorticoids, the 
activity of the GR can be regulated by several post-translational modifications (PTMs), such 
as phosphorylation, which influences the activity and protein-protein interactions of the 
receptor. Interestingly, phosphorylation of GR can alter the anti-inflammatory capabilities 
of the receptor. This study aimed to characterize the long-range interactions in GR target 
gene regulation, and to clarify how small ubiquitin-related modifier (SUMO) modification 
(SUMOylation) could influence the GR activity in a genome-wide fashion. The expression 
of FK506-binding protein 51 (FKBP51) was found to be regulated by GR via distal intergenic 
and intronic enhancers which were bordered by the CCCTC-binding factor-cohesin 
complexes. These complexes are thought to participate in chromatin loop formation, while 
the intergenic regulatory region of FKBP51 was identified as a super-enhancer. In addition, 
the present ChIP-seq analyses were among the first to demonstrate that SUMO-2/3 or 
SUMOylated proteins can bind to chromatin and, that they are associated with active 
chromatin and transcription. SUMOylation of GR has been previously postulated to restrict 
the transcriptional activity of the receptor, but its role in the genuine chromatin 
environment has not been previously addressed in a genome-wide fashion. Transcriptome 
and ChIP-seq analyses from isogenic HEK293 cells stably expressing either wild-type GR or 
SUMOylation-defective GR revealed that the basal SUMOylation sites of GR were able to 
modulate gene expression and chromatin occupancy of the receptor in a locus-selective 
fashion, influencing both glucocorticoid up- as well as down-regulated genes. However, 
not all GR target genes were sensitive to GR SUMOylation. Interestingly, GR SUMOylation 
significantly influenced the glucocorticoid regulation of anti-proliferative gene programs, 
which was manifested in the growth of the cells. On the other hand, oxidative stress-
triggered hyper-SUMOylation of GR induced by 15-deoxy-Δ12,14-prostaglandin J2, was 
associated with inhibition of GR signaling. The inhibition ensures activation of other cell 
stress associated-TFs, such as hypoxia-inducible factor 1α that would otherwise be 
repressed by GR. The results in this thesis work indicate that basal GR SUMOylation and 
cell stress-induced hyper-SUMOylation have different consequences on glucocorticoid 
signaling. 
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TIIVISTELMÄ 
 
Glukokortikoidit säätelevät elintärkeitä biologisia prosesseja vaikuttamalla geenien 
luentaan glukokortikoidireseptori (GR)-välitteisesti. Glukokortikoidit estävät tulehdusta ja 
solukasvua, minkä vuoksi niitä käytetään laajalti sekä tulehdussairauksien että 
hematologisten syöpien hoidossa. Geenin luennan muutos GR:n kromatiinille sitoutumisen 
vaikutuksesta johtuu lisäksi muiden transkriptiotekijöiden, säätelyproteiinien eli 
koregulattorien aktiivisuuden muutoksesta ja kromatiinirakenteen muokkauksesta. 
Genominlaajuiset analyysit ovat osoittaneet GR:n paljolti sitoutuvan kaukana transkription 
aloituskohdasta sijaitseville vahvistajaelementeille, minkä vuoksi pitkän matkan 
vuorovaikutukset ovat olennaisia GR:n kohdegeenien luennan säätelyssä. 
Glukokortikoidien lisäksi GR:n aktiivisuutta säätelevät myös proteiinisynteesin jälkeiset 
kovalentit modifikaatiot, kuten fosforylaatiolla, jotka vaikuttavat sekä reseptorin 
aktiivisuuteen että proteiini-proteiini vuorovaikutuksiin. Proteiinimodifikaatioiden onkin 
osoitettu vaikuttavan GR:n tulehdusta estävään toimintaan. Tämä tutkimus pyrki 
selvittämään GR:n kohdegeenien säätelyä pitkän matkan vuorovaikutuksilla sekä 
selvittämään kuinka SUMO (small ubiquitin-related modifier) proteiinimodifikaatio 
vaikuttaa GR:n aktiivisuuteen. Työni käyttää genominlaajuisia tekniikoita. Työssä 
osoitettiin GR:n säätelevän FKBP51-geeniä distaalisten intergeenisten ja intronisten 
vahvistajaelementtien kautta, jotka ovat CTCF-kohesiini-kompleksien reunustamat. Em. 
kompleksit vaikuttavat pitkän matkan vuorovaikutuksiin. Lisäksi osoitimme ensimmäisten 
joukossa, että SUMO-proteiinit tai SUMO:lla kovalentisti muokkautuneet (SUMOloituneet) 
proteiinit sitoutuvat kromatiinille ja että ne ovat liittyneinä aktiiviseen kromatiiniin ja 
transkriptioon. GR:n SUMOlaation on aiemmin ehdotettu rajoittavan reseptorin 
transkriptionaalista aktiivisuutta, mutta SUMOlaation roolia ei ole analysoitu kattavasti 
oikeassa kromatiiniympäristössä. Transkriptomi- ja kromatiini-immunopresipitaatioon 
(ChIP) liitetty tehosekvensointi (ChIP-seq)-analyysit isogeenisistä HEK293 soluista, jotka 
ilmentävät stabiilisti joko villityypin tai SUMOlaatioon kykenemätöntä GR:a osoittivat, että 
GR:n SUMOlaatio vaikutti sekä geenien luennan säätelyyn että reseptorin kromatiinille 
sitoutumiseen lokus-selektiivisesti. SUMOlaation vaikutukset näkyivät sekä 
glukokortikoideilla ylös- että alassäädellyissä geeneissä, mutta GR:n SUMOlaatio ei 
vaikuttanut kaikkiin GR:n kohdegeeneihin. GR:n SUMOlaatio vaikutti merkittävästi 
solukasvua estävien geeniohjelmien säätelyyn, mikä näkyi myös solujen kasvunopeudessa. 
Toisaalta, 15-deoxy-Δ12,14-prostaglandiini J2:n aiheuttama oksidatiivinen solustressi aiheutti 
GR:n hyper-SUMOlaatiota, minkä seurauksena GR:n signalointi vaimentui. Vaimentamisen 
seurauksena solustressiin liitetyt transkriptiotekijät aktivoituivat. Väitöskirjan tulosten 
perusteella GR:n perustason SUMOlaatiolla ja solustressin aiheuttamalla hyper-
SUMOlaatiolla on erilainen merkitys glukokortikoidisignaloinnin säätelyssä. 
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 1 Introduction  
Secretion of glucocorticoids is regulated by the hypothalamic-pituitary-adrenal (HPA) axis 
in response to various endogenous and external stimuli such as stress and cytokines. 
Glucocorticoids play an important role in the regulation of glucose metabolism, but they 
are also crucially involved in the regulation of immune function, since glucocorticoids exert 
powerful anti-inflammatory effects. The latter regulation is thought to be mainly due to the 
capabilities of glucocorticoid receptor (GR) to inhibit the action of pro-inflammatory 
transcription factors. Glucocorticoids are beneficial in the treatment of various 
inflammatory diseases, such as asthma and arthritis, and they are also used in cancer 
therapy, especially in the treatment of hematological malignancies. 
GR is a hormone-controlled transcription factor belonging to the nuclear receptor 
superfamily. The GR is activated by natural and synthetic glucocorticoids. Upon binding of 
the ligand, the GR dissociates from the heat shock chaperone complex, and moves to the 
nucleus, where it dimerizes and binds with high-affinity to short DNA sequences, 
glucocorticoid response elements, in the regulatory region of target loci. Through these 
sites, the GR can influence the activity of transcription by inducing the recruitment of 
various coregulators possessing histone-modifying and chromatin-remodeling activities. 
Genome-wide binding analyses have indicated that the GR-binding sites largely 
reside in the intronic and intergenic regions that are distal to the target gene promoter and 
transcription start site. The chromatin loops that are maintained by CTCF and cohesin are 
likely to participate in the mediation of some kind of long-range interaction between the GR 
and its target gene promoters. The long-range regulation of FK506-binding protein 51 
(FKBP51) by GR was characterized in this thesis. The FKBP51 gene is a sensitive biomarker 
of corticosteroid responsiveness. 
In addition to activating the GR, glucocorticoids induce post-translational 
modifications (PTMs) in the receptor which alter the activity and protein-protein 
interactions of the receptor. The functional group which can be attached in the PTMs can 
range from small chemical groups, such as phosphate or acetyl, to small proteins, such as 
ubiquitin or small ubiquitin-related modifier (SUMO). The stoichiometry of SUMO 
modification (SUMOylation) is low, but cell stress, such as heat and oxidative stress, can 
increase the level of protein SUMOylation, resulting in hyper-SUMOylation of target 
proteins. Simple reporter gene assays indicate that SUMOylation restricts the GR’s 
transcriptional activity, but previously the role of GR SUMOylation in the regulation of 
endogenous target genes has not been extensively studied.  
The goal of this work, was to study the genome-wide impact of GR SUMOylation on 
target gene regulation and receptor chromatin binding. This thesis aimed at clarifying the 
impact of GR SUMOylation both in normal cell growth and under cell stress conditions 
induced by exposure to the electrophilic compound, 15-deoxy-Δ12,14-prostaglandin J2. 
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2 Review of Literature 
2.1 CHROMATIN AND GENE REGULATION 
The human genome consists of three billion bases forming 22 autosomes and two sex 
chromosomes that encode 20 000 – 30 000 protein-coding genes. Although the human 
genome has around 10 000 less genes than a grapefruit and only around 10 000 more genes 
than a fruit fly, the fine-tuned and complex regulation of human genes represents the basis 
for the complex nature of humans and their society. Gene expression is an enzymatic 
process where information from DNA is converted to RNAs (transcription), and further to 
proteins (translation) which are the main cellular actors. Transcription is regulated by the 
binding of transcription factors (TFs) and coregulators to chromatin that influences the 
formation of the pre-initiation complex and also the activity of RNA polymerase II (PolII). 
While the protein-coding genes occupy only ~1% of the human genome, over 80% of the 
genome has been assigned to at least one biochemical function in at least one cell-type. 
These biochemical functions include shifts in chromatin accessibility of enhancers or 
promoters and binding of TFs to chromatin (Lander et al. 2001, ENCODE Project 
Consortium et al. 2007, Pertea & Salzberg 2010, ENCODE Project Consortium et al. 2012). 
The biochemical functions are attributable to cell-type specific patterns of gene expression 
(Rivera & Ren 2013, Voss & Hager 2014), which ultimately determine the specific function 
of that cell. Furthermore, abnormal alterations in these patterns are associated with many 
disease states. The following sections will review in more detail certain important topics 
involved in gene regulation. 
2.1.1 Histone modifications 
The human genome is packed around nucleosomes where 147 bp of DNA is wrapped 
around an octamer of four core histones; H2A, H2B, H3 and H4 (Kouzarides 2007, Li et al. 
2007). The non-condensed nucleosomes form the so-called “beads-on-a-string” 
organization, which is the primary structure of chromatin. Linker histone H1 folds 
neighboring nucleosomes together, resulting in the formation of chromatin fibers. The 
density of the chromatin fiber defines whether the chromatin is accessible (euchromatin) or 
inaccessible (heterochromatin) to TFs and PolII. The packing of DNA in this fashion is 
highly efficient, as it results in 10 000 – 20 000 fold compaction (Luger et al. 2012, Zentner & 
Henikoff 2013).  
The accessibility of chromatin is regulated by covalent and non-covalent modifications 
of nucleosomes. Covalent modifications of histones, especially in the N-terminal “tails” of 
the core histones, can influence the wrapping of DNA around the nucleosomes, and act as 
binding “docks” for different coregulators. Furthermore, specific histone modification at 
promoters, transcription start sites (TSSs), gene bodies or at enhancers can be associated 
with the activity of the promoters or enhancers (Kouzarides 2007, Li et al. 2007). Over 100 
different covalent modifications of histones have been discovered to date, ranging from 
phosphorylation to SUMOylation. The most well-known and extensively studied covalent 
modifications, are acetylation of lysine (K) residues and methylation of K and arginine (R) 
residues (Kouzarides 2007, Li et al. 2007, Zentner & Henikoff 2013).  
Histone acetylation was the first described histone modification to be linked with 
transcriptional activation. One reason is that acetylated K residues carry a positive charge 
that weakens the interaction between the nucleosome and DNA. This results in the 
formation of loose and accessible chromatin for TFs and PolII. On the other hand, 
4 
 
 
deacetylation of histones results in a stronger interaction between nucleosomes and DNA, 
resulting in the creation of inaccessible chromatin (Li et al. 2007, Zentner & Henikoff 2013). 
Acetylation of different K residues in different histones has been shown to be associated 
with highly expressed genes. H3K9 acetylation tends to be enriched at the TSS of actively 
transcribed genes, whereas acetylation at H3K27 and H4K12 is enriched at the enhancers, 
promoters and in the transcribed regions of active genes. This indicates that histone 
acetylation is associated with binding of TFs, and with both initiation- and elongation-
competent PolII. Histone acetylation itself does not dictate gene expression, but it most 
likely prepares the chromatin for transcriptional activation (Kouzarides 2007, Li et al. 2007, 
Wang et al. 2008, Heintzman et al. 2009). 
In comparison to acetylation, histone methylation is linked to both activation and 
repression of transcription. The best understood histone methylation reactions linked to 
gene activation are H3K4 mono (me1)-, di (me2)-, and tri (me3)-methylation and 
H3K36me3, whereas H3K9me3 and H3K27me3 have been associated with gene repression 
and heterochromatin formation (Li et al. 2007, Hon et al. 2009). There are several other 
histone methylations that have been reviewed elsewhere (Jenuwein & Allis 2001, 
Ruthenburg et al. 2007, Li et al. 2007, Kouzarides 2007, Barski et al. 2007, Campos & Reinberg 
2009, Greer & Shi 2012).  
While all H3K4 methylation marks are linked to active transcription, they appear 
mostly at different genomic localizations. H3K4me1 is enriched at enhancers, whereas 
H3K4me3 is predominantly concentrated at promoters and TSSs (Barski et al. 2007, Li et al. 
2007, Zentner & Henikoff 2013). The intermediate form of these two, H3K4me2, is enriched 
at both promoters and enhancers (Barski et al. 2007, Heintzman et al. 2007). Interestingly, 
whereas H3K4me3 modification at promoters is stable across different cell-types, the 
presence of H3K4me1 at enhancers seems to be cell-type dependent, and thus it can 
contribute to cell-type specific gene expression patterns (Heintzman et al. 2009). In addition, 
there can also be a large overlap between H3K4me1 and H3K4me3 modification at 
enhancers (Robertson et al. 2008). The enhancers marked with H3K4me1 in the early 
developmental phase are primed to receive developmental signals (Rada-Iglesias et al. 
2011). H3K36me3 differs from H3K4 methylation in that it is enriched in actively 
transcribed regions, i.e. in gene bodies. For this reason, H3K36me3 is thought to be 
associated with elongating PolII (Barski et al. 2007, Li et al. 2007, Zentner & Henikoff 2013). 
Furthermore, H3K36me3 is enriched more at exons than introns, evidence for a possible 
role in facilitating efficient splicing (Kolasinska-Zwierz et al. 2009). The repressive histone 
modifications H3K27me3 and H3K9me3 are enriched at silent gene promoters and at 
heterochromatin, respectively (Barski et al. 2007, Li et al. 2007, Rivera & Ren 2013). 
Interestingly, H3K27me3 has been associated with H3K4me1 at poised enhancers and 
H3K4me3 at poised promoters, respectively (Bernstein et al. 2006, Rada-Iglesias et al. 2011, 
Rivera & Ren 2013). 
Non-covalent modification of histones involves pioneer or chromatin-remodeling 
factors, that slide, replace or evict the whole or at least a part of the nucleosomes from the 
DNA creating accessible binding sites for TFs and PolII. There is also an interplay between 
covalent and non-covalent histone modifications, due to the fact that acetylated histone 
“tails” can be recognized by chromatin-remodeling factors, which alter the nucleosome 
position (Jiang & Pugh 2009, Dechassa et al. 2010, Rivera & Ren 2013). The chromatin-
remodeling factors along with other TFs and coregulators will be discussed in the next 
section.  
2.1.2 Transcription factors and coregulators 
Humans express more than 2 000 TFs which can be divided into constitutive and regulatory 
TFs. The latter type can be further divided into developmental and signal-dependent TFs. 
Most of the TFs seem to belong to the signal dependent TFs (Brivanlou & Darnell 2002). TFs 
bind in response to endogenous or external stimuli to regulatory regions in the chromatin 
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where they promote or inhibit transcription via the recruitment of additional TFs and 
coregulators that influence the chromatin accessibility and the activity of PolII (Komili & 
Silver 2008, Ong & Corces 2011, Maston et al. 2012) (Fig. 1). Usually TFs have to bind 
cooperatively in order to gain access to enhancers and promoters in compact chromatin. 
However, a class of TFs, called pioneer TFs, such as forkhead protein A1 (FoxA1) and 
GATA binding protein family members, are capable of binding to compact chromatin by 
themselves and facilitating the binding of other TFs (Zaret & Carroll 2011, Jozwik & Carroll 
2012, Maston et al. 2012, Zhang & Glass 2013, Voss & Hager 2014).  
 
 
 
Figure 1. Sequential process depicting TF recruitment to an enhancer and activation of 
transcription. (Reprinted from Maston et al. 2012 with permission of Annual Reviews.) 
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Most TFs bind directly to DNA, usually to specific sequences called motifs or response 
elements. However, there are TFs that do not bind DNA, but instead they become attached 
to other TFs or histones. After binding to chromatin, the TFs recruit different coregulators 
in a sequential process that influences chromatin accessibility and PolII activity (Rosenfeld 
et al. 2006, Maston et al. 2012, Zhang & Glass 2013). Over 350 different coregulators have 
been identified; they are divided into coactivators or corepressors depending on how they 
influence gene expression (Perissi & Rosenfeld 2005, Lonard & O’Malley 2007, Lonard & 
O’Malley 2012). During gene activation, many TFs first recruit coactivators, such as steroid 
receptor coactivator (SRC) family members, to chromatin. Many of these TFs possess weak 
histone acetyltransferase (HAT) activity and thus they acetylate nucleosomes and weaken 
the interaction between DNA and histones, creating more accessible chromatin region to 
other TFs and PolII. However, rather than acetylating the nucleosomes by themselves, they 
usually recruit stronger HAT activity-containing coactivators, such as p300 or cAMP 
response element-binding protein (CREB)-binding protein (CBP), that are able to acetylate 
nucleosomes more efficiently (Perissi & Rosenfeld 2005, Malovannaya et al. 2011). The 
process of coregulator recruitment is similar during gene repression, where recruited 
corepressors contain histone deacetylase (HDAC) activity instead of HAT activity, 
strengthening the interaction between DNA and the histone.  
As mentioned above, chromatin-remodeling complexes are important in the 
regulation of chromatin accessibility. These coregulators which consist of multiple subunits, 
are ATP-dependent, and they can function both as coactivators as well as corepressors 
(Perissi & Rosenfeld 2005, Cairns 2009). Chromatin-remodeling complexes are important 
regulators of mammalian development and factors maintaining pluripotency: e.g. single 
knockout of various subunits results in embryonic lethality in mice (Ho & Crabtree 2010). 
Nucleosome remodeling by SWItch/Sucrose NonFermentable (SWI/SNF) chromatin-
remodeling complex demonstrated to occur in two distinct phases. In the first phase, the 
H2A/H2B dimer is rapidly removed from the nucleosome, followed by a second, slower 
phase where the rest of the nucleosome is evicted from the chromatin (Dechassa et al. 2010). 
The cooperative function of SWI/SNF complexes with TFs has been shown to be important 
in the creation of accessible chromatin in the promoter regions of activated genes (George et 
al. 2009, Li et al. 2010a). In addition, a recent study revealed that there was a notable overlap 
of different chromatin-remodeling complexes at the same accessible chromatin site. Many 
of the sites require the action of at least two chromatin-remodeling complexes (Morris et al. 
2014). Interestingly, dysfunctions in many coregulators including chromatin-remodeling 
complexes have been implicated in several different diseases states, such as cancer, making 
them potential drug targets (Weissman & Knudsen 2009, Lonard & O’Malley 2012). 
Many recent genome-wide studies have shown that various TFs, such as nuclear 
receptors (NRs), do not generally bind in the proximal promoter of their target genes but 
rather their enhancer binding sites resided far away in the intronic and intergenic regions 
(Welboren et al. 2009, Yu et al. 2010, John et al. 2011, Uhlenhaut et al. 2013, Ding et al. 2013). 
According to a recent study, the median distance between promoter and enhancer region 
was estimated as 124 kb (Jin et al. 2013). In order to TFs in the enhancers to interact and 
recruit PolII to promoter, there needs to be chromatin loops which can bring these two into 
contact with each other (Ong & Corces 2011). These chromatin loops are thought to be 
maintained by CCCTC-binding factor (CTCF) along with cohesin (Wendt et al. 2008, 
Schmidt et al. 2010). Interestingly, the latter factor has been shown to function as an anchor 
site to which TFs can bind in dense clusters (Yan et al. 2013). In addition, many of the 
chromatin loops are already pre-existing prior to the appearance of any activating or 
repressing signals (Jin et al. 2013). A large portion of the promoter-enhancer interactions are 
interchromosomal, but only a small portion of the intrachromosomal promoter-enhancer 
interactions are linked to the nearest TSS (Zhang et al. 2013). 
Since the DNA in the exons codes for amino acids by codons, simultaneously the same 
stretch of DNA can function as a part of motif for TF binding. This aspect was recently 
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revealed by Stamatoyannopoulos and colleagues (Stergachis et al. 2013), who found that 
around 15% of the human codons function also as TF recognition sites. Even though a 
single-nucleotide variation in the exons might not influence the translated amino acid due 
to “wobble” base, it may be able to alter the TF binding to that particular site. This suggests 
that during human evolution a code has evolved within a code.  
2.2 GLUCOCORTICOID RECEPTOR 
The human glucocorticoid receptor (GR) is encoded by the nine exons of the NR3C1 gene 
that is located on the long arm of chromosome 5. The gene encodes two primary splice 
variants of the receptor, with the GRα consisting of 777 amino acids and GRβ containing of 
742 amino acids. The splice variants are identical up to amino acid 727, differing only in the 
splicing of exon nine (Hollenberg et al. 1985, Oakley & Cidlowski 2011, Oakley & Cidlowski 
2013). In addition, GRα has multiple translational isoforms differing in the N-terminal 
domain (NTD). The GRβ mainly antagonizes the action of GRα. The function of GRβ has 
been reviewed in more detailed elsewhere (Yudt et al. 2003, Lu & Cidlowski 2004, Lewis-
Tuffin & Cidlowski 2006, Oakley & Cidlowski 2013). GR is a member of the steroid receptor 
(SR) family within the NR superfamily of TFs. NRs are signal dependent DNA-binding TFs 
that bind with high affinity to short DNA sequences called hormone response elements 
(HREs). Other members of SRs, such as androgen receptor (AR), estrogen receptor (ER), 
mineralocorticoid receptor (MR), and progesterone receptor (PR), share a similar modular 
structure and are involved in the hormone-dependent regulation of genes and gene 
programs as the GR (Aranda & Pascual 2001, Chawla et al. 2001, Heitzer et al. 2007). This 
aspect will be discussed in more detail in the following sections. 
GR is expressed in virtually all human cells and the physiological role of GR is to 
mediate the effects of glucocorticoids. The secretion of glucocorticoids is regulated by the 
hypothalamic-pituitary-adrenal (HPA) axis. This secretion is subjected to a circadian 
rhythm, with the level of glucocorticoids in the blood being highest in the morning and 
lowest at midnight/late-night. In response to endogenous or external stimuli, the 
periventricular nucleus of the hypothalamus secretes corticotropin-releasing hormone 
(CRH) that in turn stimulates the synthesis and secretion of adrenocorticotropic hormone 
(ACTH) in the anterior pituitary gland. Finally, ACTH stimulates the production of 
glucocorticoids in the zone fasciculata of the adrenal glands. The synthesized 
glucocorticoids are transported via the bloodstream to target tissues where they influence 
many crucial physiological processes, such as metabolism, cardiovascular function, 
reproduction, cognition, and skeletal growth (Rhen & Cidlowski 2005, Quax et al. 2013, 
Oakley & Cidlowski 2013). One of the most important physiological processes regulated by 
glucocorticoids is the immune system. Glucocorticoids exert strong anti-inflammatory 
effects by inhibiting pro-inflammatory and cytokine-mediated signaling pathways as well 
as inducing apoptosis and cell cycle arrest of cells in the immune system. Due to these 
effects, glucocorticoids are used in the treatment of various inflammatory disorders, such as 
allergies, asthma, and sepsis, as well as in the treatment of hematological malignancies 
(Smoak & Cidlowski 2004, Rhen & Cidlowski 2005, Clark & Belvisi 2012, Dejager et al. 
2014). The anti-inflammatory effect of glucocorticoids in the level of gene regulation will be 
reviewed in the section 2.2.3.  
2.2.1 Structure 
As mentioned earlier, the GR modular structure is similar to that of the other SRs, 
consisting of five different domains (Fig. 2); NTD, DNA-binding domain (DBD), hinge 
region and ligand-binding domain (LBD). The latter site is also known as C-terminal 
domain (CTD) (Aranda & Pascual 2001, Chawla et al. 2001, Heitzer et al. 2007, Oakley & 
Cidlowski 2013). The NTD is the largest domain in the GR and it is highly variable between 
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SRs. It also harbors one of two transcriptional activation regions (AF)-1, through which GR 
can interact with other TFs, coregulators and pre-initiation complexes in a cell- and 
promoter-specific manner. The precise interaction motif has not been found, but it is known 
that disruptions in the AF-1 has reduced GR activity in a reporter gene assay (Kumar & 
Thompson 2005, Kumar & Thompson 2012). AF-1 in GR also contains two conserved 
synergy control (SC) motifs that restrict the transcriptional activity of the receptor in 
promoters containing multiple GR-binding sites (Iñiguez-Lluhí & Pearce 2000). The link 
between GR SUMOylation and the SC motifs will be reviewed in section 2.2.2.4.5.  
Next to the AF-1 is the DBD and this is one of the most extensively studied domains of 
the GR and the most conserved region among SRs. In the DBD, eight conserved cysteine (C) 
residues form two zinc finger structures with two Zn atoms. The first zinc finger is 
responsible for the DNA binding in the major groove of the GR’s HRE, called the 
glucocorticoid response element (GRE). The second zinc finger is necessary for receptor 
dimerization (Kumar & Thompson 2005, Heitzer et al. 2007). Interestingly, the DNA 
sequence of the GRE does not function merely as a docking site for GR, but it also 
influences the transcriptional activity of the GR by altering the conformation of the lever 
arm, a region between the zinc fingers (Meijsing et al. 2009). Furthermore, the same region 
along with dimerization interface in the second zinc finger has been shown to facilitate 
allosteric communication from the DNA-bound GR to its dimer partner (Watson et al. 2013). 
In light of these facts, a single amino acid change in the lever arm is sufficient to change the 
binding pattern of the GR (Thomas-Chollier et al. 2013). The hinge region is adjacent to the 
DBD; this contains the constitutive active nuclear localization signal (NLS). The region is 
highly variable and it enables the rotation of the DBD (Aranda & Pascual 2001, Heitzer et al. 
2007). In addition, the hinge region connects the DBD with the LBD.  
 
 
 
Figure 2. Modular structure of the human GR (777 amino acids). Linear presentation of GR 
structure where the major sites for PTMs are depicted: phosphorylation sites (P) below and 
SUMOylation (S), ubiquitylation (U) and acetylation (A) sites above the functional domains of 
the receptor, respectively. The numbering is based on the accession number P04150 in 
Universal Protein Resource. N, the amino terminus; C, carboxy terminus; NTD, the N-terminal 
domain; DBD, DNA-binding domain; H, hinge region; LBD, ligand-binding domain; P, 
phosphate; S, SUMO; U, ubiquitin; A, acetyl. 
 
Along with the DBD, the LBD has been the most widely studied domain of the GR. In 
addition to ligand binding, the LBD influences receptor dimerization, and folding by 
interacting with heat shock protein (HSP) 90 complex. Furthermore, it also contains ligand-
dependent NLS. The LBD consists of 12 α-helices that fold into a globular structure creating 
a central pocket, the ligand-binding site, with helix-12 functioning as the lid of the pocket 
(Aranda & Pascual 2001, Kumar & Thompson 2005, Heitzer et al. 2007). The helix-12 
harbors the second AF(-2) of the receptor consisting of leucine (L)-xxLL motifs to allow the 
recruitment of coregulators in a ligand-dependent manner (Savkur & Burris 2004, Mahajan 
& Samuels 2005, Kumar & Thompson 2005, Oakley & Cidlowski 2013). Upon ligand 
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binding to LBD, the conformation of the helix-12 changes, exposing new surfaces in LBD 
for coregulator recruitment. The type of ligand that binds to LBD dictates whether the 
newly exposed surfaces favor coactivator or corepressor binding. The GR LBD binds both 
natural and synthetic corticosteroids, which are classified as either agonists or antagonists 
according to the way that they influence GR’s transcriptional activity (Clark & Belvisi 2012, 
Oakley & Cidlowski 2013). 
2.2.2 Post-translational modifications 
One significant way to increase and fine-tune the function of proteins is post-translational 
modifications (PTMs) that involve the attachment of a functional group into a specific 
amino acid residue of the target protein. The functional groups can be small chemical 
groups, such as phosphate (phosphorylation) or acetyl (acetylation), or more complex 
molecules, such as isoprenoid (isoprenylation) or sugar (glycosylation), or other small 
proteins, such as ubiquitin (ubiquitylation) or small ubiquitin-related modifier (SUMO) 
(SUMOylation) (Deribe et al. 2010, Cubeñas-Potts & Matunis 2013, Beltrao et al. 2013, Wang 
et al. 2014). Thus the histone modifications discussed earlier, are examples of PTMs 
(Kouzarides 2007). Clearly, PTMs are highly important regulators of protein functions, as 
they are involved in practically all cellular events, such as gene expression, signal 
transduction and protein-protein interaction. All the SRs, including GR are targeted by 
PTMs (Anbalagan et al. 2012, Oakley & Cidlowski 2013) (Fig. 2). The PTMs regulating GR 
function are reviewed in the next sections. 
2.2.2.1 Phosphorylation 
The most extensively studied PTM of GR is phosphorylation. In this situation a phosphate 
group from ATP is covalently attached to the hydroxyl group of serine (S), threonine (T) or 
tyrosine (Y) residues. Protein kinases are enzymes that transfer the phosphate group from 
ATP to the target proteins. These enzymes mediate the majority of signal transduction in 
eukaryotic cells. Conversely, phosphatases remove the phosphate group from target 
proteins (Manning et al. 2002). Eleven amino acid residues in the GR are known to be 
targeted by a phosphate group; 10 to the S residue and 1 to the T residue. Practically, all of 
the 11 phosphorylation sites in human GR are located in the NTD and 7 of 11 are located 
within the AF-1 (Ismaili & Garabedian 2004, Beck et al. 2011, Oakley & Cidlowski 2013). The 
major kinases phosphorylating the GR are cyclin-dependent- (CDK), glycogen synthase- 
(GSK), c-JUN N-terminal- (JNK) and mitogen-activated protein (MAPK) kinases. Little is 
known about the phosphatases removing phosphorylation from GR (Galliher-Beckley & 
Cidlowski 2009, Clark & Belvisi 2012, Oakley & Cidlowski 2013).    
The best characterized phosphorylation sites in the GR are S134, S203, S211, S226 and 
S404 and of these S203 and S226 can be phosphorylated both in the absence or presence of 
dexamethasone (dex), a synthetic agonist of GR. Instead the phosphorylation of S211 
appears to be agonist-dependent (Wang et al. 2002, Blind & Garabedian 2008, Galliher-
Beckley & Cidlowski 2009). Interestingly, S211 has been shown to be a biomarker of 
activated GR (Wang et al. 2002) and it has been associated with the transcriptional activity 
of GR, whereas phosphorylation of S226 decreases the activity of GR (Blind & Garabedian 
2008, Chen et al. 2008, Galliher-Beckley & Cidlowski 2009, Oakley & Cidlowski 2013). Even 
though phosphorylations of S211 and S226 have opposite effects on the GR activity, neither 
of them inhibits GR binding to chromatin (Blind & Garabedian 2008). Both 
phosphorylations alter the conformation of GR, facilitating differential coregulator 
recruitment. For instance, phosphorylation of S211 enhances the interaction of GR with 
MED14, a component of the mediator complex (Chen et al. 2008). This interaction does not 
occur in all regulatory regions of GR target genes, indicating that the effect of S211 
phosphorylation on gene regulation is both gene- and promoter-specific. GR 
phosphorylated at S203 is predominantly found in the cytoplasm (Wang et al. 2002), and it 
10 
 
 
does not bind to chromatin (Blind & Garabedian 2008), suggesting that the modification 
represses GR activity (Galliher-Beckley & Cidlowski 2009).    
Phosphorylation of GR at S404 has a major impact on the receptor function, due to the 
fact that it inhibits GR’s ability to induce and repress its target genes. This occurs because 
phosphorylation of S404 alters the conformation of the GR, resulting in a reduced 
interaction between GR and coactivator p300/CBP and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) subunit p65 (Galliher-Beckley et al. 2008, Galliher-
Beckley & Cidlowski 2009). S134 phosphorylation is distinct from the other GR 
phosphorylations, since it is not induced by an agonist, but instead by stress conditions, 
such as oxidative stress. This stress-induced phosphorylation increases the interaction of 
GR with the zeta isoform of the 14-3-3 class of signaling proteins (Galliher-Beckley et al. 
2011, Oakley & Cidlowski 2013).  
2.2.2.2 Acetylation 
Acetylation involves the attachment of an acetyl group from acetyl-coenzyme A to K 
residues in the target protein. As mentioned earlier, acetylation of histone “tails” has been 
linked to transcriptional activation, and histone “tails” are acetylated by proteins 
possessing HAT activity. Despite the name, the HAT activity-containing proteins can 
acetylate non-histone proteins, such as SRs. This is also true for the HDAC activity-
containing proteins that remove the acetyl groups from the target proteins.  
There are four K residues in GR known to act as targets for acetylation reactions. 
Three of the acetylation sites are located in the hinge region, the other one is in the DBD. 
Furthermore, they all are localized at the junction of the DBD and the hinge region (Beck et 
al. 2011, Oakley & Cidlowski 2013). Acetylation of K494 and K495, the first acetylation sites 
described in GR, has been shown to be important for the regulation of NF-κB-dependent 
gene expression. Deacetylation of these sites by HDAC2 enhances the interaction of GR 
with p65, attenuating pro-inflammatory gene expression (Ito et al. 2006). Interestingly, 
while the loss of HDAC2 inhibited the interaction between GR and p65, it did not affect GR 
translocalization to the nucleus, chromatin binding or its ability to induce gene expression. 
These results suggest that acetylation of GR at K494 and K495 restricts the inhibitory 
function of glucocorticoids on pro-inflammatory NF-κB signaling (Ito et al. 2006, Oakley & 
Cidlowski 2013).  
Interestingly, measurement of acetylation status of GR from peripheral blood 
mononuclear cells indicated that the acetylation was higher in the morning as compared to 
the evening. This is due to master regulator of circadian rhythms called the circadian 
locomotor output cycles kaput (CLOCK) that acetylates GR at K480, K492, K494 and K495 
residues (Nader et al. 2009, Charmandari et al. 2011). CLOCK-mediated acetylation has 
inhibited the GR’s ability to induce and repress its target genes, indicating that CLOCK 
functions as circadian negative regulator of GR. Interestingly, while the acetylation of 
histone “tails” is linked to active transcription, GR acetylation seems to attenuate the 
activity of the receptor. 
2.2.2.3 Ubiquitylation 
Chains of ubiquitin target proteins to undergo proteasomal degradation (Ciechanover et al. 
1980, Hershko et al. 1980). This discovery led to the award of the Nobel Prize in chemistry 
in 2004. Ubiquitin is a small (8.5 kDa) and stable regulatory protein that folds into a 
compact β-grasp fold with a flexible C-terminal tail. The fold is called the ubiquitin fold, 
and it is also found in other ubiquitin-like proteins, including SUMO. Ubiquitin is 
conjugated from its C-terminal tail by isopeptide bond to K residues of target proteins via 
three step cascade that involves activating (E1), conjugating (E2) and ligase (E3) enzymes. 
During activation, the thiol side chain in C residue from E1 enzyme reacts with ubiquitin, 
creating a thiol ester bond between them, which consumes energy from ATP. In the next 
step, ubiquitin is transferred from the E1 to the conjugating E2 enzyme that subsequently 
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interacts with E3 ligases that recruit and bind a specific substrate. In the final step, E3 ligase 
transfers ubiquitin to the substrate. Conjugation of ubiquitin can be monomeric 
(monoubiquitylation) or polymeric, e.g. formation of ubiquitin chains 
(multi/polyubiquitylation) that can occur in one K residue in a homogenous, branched or 
mixed manner (Hicke 2001, Pikart & Eddins 2004, Komander & Rape 2012). Ubiquitin can 
be removed from proteins by deubiquitinases that cleave the isopeptide bond between the 
K of the substrate and the C-terminal tail of ubiquitin (Komander & Rape 2012). 
Interestingly, ubiquitylation, especially monoubiquitylation, can also regulate several non-
proteolytic functions. These functions include regulation of protein activity, localization 
and protein-protein interactions (Hicke 2001, Schnell & Hicke 2003, Komander & Rape 
2012). One such example is the monoubiquitination of histone H2A and H2B, which 
influences the initiation and elongation of transcription and is involved in DNA repair 
(Weake & Workman 2008). 
Only the K419 residue, localized in PEST motif at the NTD near to the junction with 
DBD, has been found to be targeted by ubiquitin in GR (Wallace et al. 2010). The PEST motif 
is a region enriched with proline (P), glutamic acid (E), S and T residues that are usually 
flanked by charged amino acids. Several proteins are rapidly degraded via their PEST 
sequences (Rogers et al. 1986). Treatment of proteasomal inhibitor MG132 increased the 
accumulation of GR protein level, suggesting that GR is a target of the ubiquitin-
proteasome pathway (Wallace & Cidlowski 2001, Deroo et al. 2002, Wallace et al. 2010). 
Furthermore, K419 was found to be the target of ubiquitin. In addition, the inhibition of 
proteasome function increased GR-mediated transactivation and reduced GR mobility 
within the nucleus. However, the K419 site did not influence translocalization of GR into 
and out of the nucleus (Deroo et al. 2002, Wallace et al. 2010). Interestingly, while the 
transactivation of GR was increased by inhibition of proteasome function, the 
transactivation of ER was conversely reduced (Reid et al. 2003). Furthermore, inhibition of 
proteasome function disrupts the sequential formation of AR and ER transcription 
complexes in the regulatory region of their target genes (Kang et al. 2002, Reid et al. 2003). 
However, overexpression of ubiquitin E3 ligase carboxy terminus of HSP70-interacting 
protein (CHIP) can reduce GR transactivation after proteasomal inhibition (Wang & 
DeFranco 2005). This indicates that the differential response to proteasomal inhibition 
depends on the expression level of the ubiquitin E3 ligases. 
2.2.2.4 SUMO modification pathway 
2.2.2.4.1 SUMO proteins 
SUMO belongs to the ubiquitin-like proteins together with several other proteins that target 
cellular proteins through a similar pathway but with a different outcome than seen with 
ubiquitin (Welchman et al. 2005). Vertebrates express three SUMO paralogs, SUMO-1, -2 
and -3, that can be conjugated to target proteins. In addition, there is a fourth SUMO 
paralog, SUMO-4, but its role is unclear as seemingly it cannot exist in a mature form or be 
conjugated to proteins (Geiss-Friedlander & Melchior 2007, Flotho & Melchior 2013). 
Furthermore, as SUMO-1, -2 and -3 are ubiquitously expressed, SUMO-4 has been found to 
be expressed mainly in kidney, lymph node and spleen (Guo et al. 2004, Geiss-Friedlander 
& Melchior 2007). Several different groups initially found SUMO-1 in the mid-1990s. For 
this reason, in the early literature it received several names, such as PIC1 (Boddy et al. 
1996), UBL1 (Shen et al. 1996), GMP1 (Matunis et al. 1996) and sentrin (Kamitani et al. 1997) 
prior to the decision to name it as SUMO-1 (Mahajan et al. 1997). All SUMO proteins are 
small (~10 kDa) containing ubiquitin fold with a C-terminal glycine (G)-G motif that is 
exposed after proteolytic maturation. SUMO proteins share less than 20% sequence identity 
with ubiquitin and their overall surface-charge differs from that of ubiquitin. In addition, 
SUMO proteins differ from other ubiquitin-like proteins since they contain a flexible N-
terminus that serves as an acceptor in the formation of SUMO chains. With respect to the 
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different SUMO paralogs, SUMO-2 and SUMO-3 are almost identical with ~97% sequence 
identities. At the moment there are no antibodies that can distinguish them from each other 
and therefore, subsequently SUMO-2 and SUMO-3 will be called collectively as SUMO-2/3. 
SUMO-1 differs clearly from SUMO-2/3 since it only exhibits ~47% sequence identity with 
SUMO-2 (Geiss-Friedlander & Melchior 2007, Flotho & Melchior 2013, Cubeñas-Potts & 
Matunis 2013). Target proteins modified by SUMO may have preferences for whether they 
are SUMO-1 or SUMO-2/3–modified. SUMO paralogs in zebrafish are functionally 
redundant (Yuan et al. 2010), and the functions of SUMO-1 can be substituted by SUMO-2/3 
in mouse in vivo (Zhang et al. 2008a). Interestingly, SUMO-1 is found mostly in its 
conjugated forms whereas SUMO-2/3 tends to be unconjugated in mammalian cells (Saitoh 
& Hinchey 2000). This does not mean that all target proteins prefer SUMO-1 over SUMO-
2/3, as the expression of SUMO-2/3 is usually ten-fold higher than that of SUMO-1 (Saitoh 
& Hinchey 2000).  
 
 
 
Figure 3. Reversible SUMO modification of GR. Different steps of SUMO modification process and 
enzymes involved in these steps are depicted.  
 
2.2.2.4.2 SUMO conjugation 
Conjugation of maturated SUMOs to target proteins (Fig. 3) is initiated by the transfer of 
SUMO proteins to the heterodimeric E1 SUMO activating enzyme (SAE1/2, also known as 
Aos1/Uba2). In a two-step reaction, hydrolysis first forms the SUMO-adenylate conjugate in 
an ATP-dependent manner, and in the second step, a thioester bond is formed between 
catalytic C residue of SAE2 and C-terminal carboxy group of SUMO (Geiss-Friedlander & 
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Melchior 2007, Flotho & Melchior 2013). Subsequently, SUMO is transferred to the E2 
conjugating enzyme UBC9, where it forms a similar bond between catalytic C residue and 
the carboxy group of SUMO as with the SAE2 (Geiss-Friedlander & Melchior 2007). Unlike 
the ubiquitylation that harbors 30 different E2 conjugating enzymes, UBC9 is the sole 
SUMO E2 conjugating enzyme known at present (van Wijk & Timmers 2010). For this 
reason, knockout of Ubc9 is embryonically lethal in mice, highlighting the biological 
importance of SUMO conjugation (Nacerddine et al. 2005). UBC9 is capable of attaching 
SUMO to target proteins without SUMO E3 ligase activity, such as RanGAP1. However, 
SUMO E3 ligases enhance the SUMOylation rate and they may contribute to substrate 
specificity (van Wijk & Timmers 2010, Flotho & Melchior 2013). Protein inhibitor of 
activated STAT (signal transducers and activators of transcription) (PIAS) family members, 
PIAS1, -xα, -xβ, -3 and -y have been extensively studied SUMO E3 ligases in mammals 
(Rytinki et al. 2009). SUMO E3 ligases stabilize the interaction between UBC9 and the 
substrate by bending the thioester bond between SUMO and UBC9. This orientation favors 
nucleophilic attack of the K residue in the target protein to SUMO (Flotho & Melchior 2013).  
2.2.2.4.3 Maturation and deconjugation of SUMO 
Prior to conjugation of SUMOs to their target proteins, they are maturated from the 
precursor-SUMO proteins. SUMOs contain C termini G-G motifs that are exposed by the 
family of sentrin/SUMO-specific proteases (SENPs). The human SENP family consists of six 
isopeptidase members, SENP1-3 and SENP5-7. Initially the family contained seven 
members, but SENP4 was found to be the same isopeptidase as SENP3. All SENP proteins 
are not able to maturate SUMOs and they can show some preference over different SUMO 
paralogs; SENP1 preferentially maturates SUMO-1, whereas SENP2 maturates SUMO-2 
(Mukhopadhyay & Dasso 2007, Hickey et al. 2012). SENPs deconjugate SUMOs from 
proteins. They are capable of removing all SUMO conjugates from target protein or only a 
certain proportion of SUMO chains. The latter process is termed chain editing 
(Mukhopadhyay & Dasso 2007). Similar to the situation with the maturation of SUMOs, 
SENPs can show preferences in the deconjugation, e.g. SENP3 and SENP6 can both 
deconjugate SUMO from target proteins, but only the latter enzyme can modify part of the 
SUMO chain (Hickey et al. 2012). The cleavage of SUMO from the substrate occurs though 
the isopeptide bond similar to the maturation of SUMO. SUMOylation of proteins is 
thought to occur in rapid cycles, resulting in low steady-state modification levels (Hickey et 
al. 2012, Flotho & Melchior 2013). Interestingly, the level of SUMOylation can be increased 
by different signals e.g. cellular stress (Golebiowski et al. 2009, Tathman et al. 2011, Rytinki 
et al. 2012).  
2.2.2.4.4 SUMO consensus sites and SIMs 
The conjugation occurs between C-terminal G of SUMO and ε-amino group of K. The K 
residue in the SUMO acceptor site in target proteins is usually found in a consensus motif 
ΨKxE/D where Ψ is a hydrophobic amino acid valine (V), L or isoleucine (I) and x is any 
amino acid residue followed by an acidic E or aspartic acid (D) residue (Flotho & Melchior 
2013). There are also other types of SUMO consensus motifs, such as the phosphorylation-
dependent SUMOylation motif (PDSM) (Hietakangas et al. 2006, Flotho & Melchior 2013). 
However, SUMO acceptor K residues have also been identified in non-consensus regions 
(Blomster et al. 2009). As mentioned above, SUMO-2/3 can form SUMO chains like 
ubiquitin via its N terminus that harbors a SUMO consensus motif. Additionally, other K 
residues in SUMO-1, SUMO-2 and SUMO-3 have been found to be able to form SUMO 
chains (Golebiowski et al. 2009, Bruderer et al. 2011, Flotho & Melchior 2013). In addition to 
covalent attachment (SUMOylation), proteins can interact with SUMO via a hydrophobic 
core motif, termed the SUMO interaction motif (SIM). SIMs usually consist of V/I-x-V/I-V/I 
or V/I-V/I-x-V/I sequence that is flanked by S or E/D residues, and it forms a short β-strand 
so that it can interact with the α-helix and the β2-strand of SUMO protein (Song et al. 2004, 
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Flotho & Melchior 2013). Multiple SIM-containing proteins have been identified, including 
components of the SUMO conjugation pathway, such as all the PIAS proteins (Kerscher 
2007, Rytinki et al. 2009, Flotho & Melchior 2013). It is thought that the SIM(s) in 
SUMOylated proteins and SUMO pathway components can facilitate the conjugation of 
SUMO.  
SIMs are also important in the cross-talk between SUMO and ubiquitin signaling 
pathways. Several really interesting new gene (RING) domain containing members of the 
ubiquitin E3 ligases are known as SUMO-targeted ubiquitin ligases (STUBLs). STUBLs 
contain multiple SIMs, through which they interact with SUMOylated proteins and target 
them for degradation by ubiquitination (Hay 2013, Flotho & Melchior 2013). The most 
widely studied STUBL is the RING finger protein 4 (RNF4), which in its NTD contains four 
SIMs, which potentially can interact with multiple SUMO proteins (Häkli et al. 2004, 
Tatham et al. 2008). Interesting, the RNF4-mediated mechanism of ubiquitination and 
subsequent degradation of SUMOylated promyelocytic leukemia (PML) is important in 
leukemia. Acute promyelotic leukemia harbors a translocation between PML gene and the 
retinoic acid receptor α (RARα) gene in chromosomes 15 and 17, respectively (Wang & 
Chen 2008). Arsenic trioxide induces poly-SUMOylation of the PML ultimately resulting in 
the ubiquitination and degradation of the fusion protein via the action of RNF4 (Tatham et 
al. 2008, Lallemand-Breitenbach et al. 2008). Interestingly, PIAS1 has also been shown to be 
important in the arsenic oxide-induced degradation of PML-RARα fusion protein 
(Rabellino et al. 2012). 
2.2.2.4.5 GR SUMOylation 
Several NRs, including GR are targeted by the SUMO modification pathway (Poukka et al. 
2000, Tian et al. 2002, Sentis et al. 2005, Pascual et al. 2005, Knutson et al. 2012). GR contains 
three K residues in a SUMO consensus motif and these are capable of conjugating SUMO, 
two in the NTD (K277 [VKTE], K293 [IKQE]) and one in the LBD (K703 [VKRE]) (Tian et al. 
2002) (Fig. 3). The latter SUMOylation site is the weakest, while the NTD sites are the 
strongest in the GR. In addition, the NTD sites seem to be conserved among the SRs, such 
as AR, MR, and PR (Poukka et al. 2000, Tirard et al. 2007, Knutson et al. 2012). Furthermore, 
SUMOylation of GR occurs in a ligand-enhanced fashion. It has been shown that the 
SUMOylation of the SC motifs (K277, K293) restricts GR’s activity in sites that contain 
multiple GREs (Le Drean et al. 2002, Holmstrom et al. 2003, Holmstrom et al. 2008). In 
addition, GR is predicted to harbor three SIMs, one between the NTD and DBD and two in 
the LBD. However, their functions have not yet been confirmed. 
Interestingly, the two NTD SUMOylation sites are within the SC motif in the AF-1 of 
GR. The SC motif consensus sequence (P-x[0-4]-I/V-KxE-x[0-3]-P) contains the SUMO 
consensus motif (Iñiguez-Lluhí & Pearce 2000, Le Drean et al. 2002). Interestingly, this 
restriction of GR transcriptional activity was not seen with a more complex MMTV 
promoter (Tian et al. 2002). It has been proposed that the restriction of transcriptional 
activity by SUMOylation relies on the recruitment of corepressor death-associated protein 6 
(DAXX) that interacts with the GR through its SIM (Lin et al. 2006). However, the inhibition 
of GR activity by DAXX was later shown to be independent of GR SUMOylation 
(Holmstrom et al. 2008). 
Initially, the SUMOylation site K703 in LBD was found to be relatively weak (Tian et 
al. 2002) and its function has remained unclear. However, recently it was shown that RING 
finger and WD repeat (RWD)-containing SUMOylation enhancer (RSUME) that is capable 
of increasing protein SUMOylation (Doerks et al. 2002, Carbia-Nagashima et al. 2007), 
enhances GR SUMOylation independently of NTD SUMO sites but it is dependent on the 
presence of the LBD SUMO site (Druker et al. 2013). Interestingly, enhancement of GR 
SUMOylation via RSUME increases the transcriptional activity of the receptor and mediates 
coactivator-mediated GR activation. Thus, the SUMOylation site in the LBD of GR may 
enable protein-protein interactions that favor enhancement of the GR’s activity. 
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  In addition to the PDSM (Hietakangas et al. 2006), SUMO and phosphorylation can 
cross-talk with each other via non-PDSM linked mechanisms. Evidence for cross-talk 
between SR SUMOylation and phosphorylation has been observed with GR and PR (Davies 
et al. 2008, Knutson et al. 2012). The S226 residue in human GR (S246 in rat, Galliher-Beckley 
& Cidlowski 2009) is phosphorylated by JNK, which seems to further facilitate the 
SUMOylation of K277 and K293 (Davies et al. 2008). The transcriptional activity of GR is 
increased as a result of inhibition of either JNK or SUMO pathway, and this inhibition has 
also been observed with a few endogenous GR target genes. However, the inhibition seem 
to be target gene-specific, suggesting that an interplay between phosphorylation of S226 
and SUMOylation of K277/K293 fine tunes the activity of GR. 
2.2.3 Function in transcriptional regulation 
Prior to the binding of the hormone to the LBD, the GR resides in the cytoplasm in a large 
chaperone complex that consists mainly of HSPs and the FK506 family of immunophilins 
(FKBP51/52) (Pratt and Toft 1997, Oakley & Cidlowski 2013). While it is still part of the 
complex, the GR remains transcriptionally inactive, although it is capable of binding 
ligands. Once certain glucocorticoids, e.g. cortisol, have entered the cell via bloodstream, 
they bind to the ligand-binding pocket of GR, causing a conformational change in the 
receptor. This change in the conformation results in the dissociation of the chaperone 
complex and exposure of the NLS in the LBD. The GR is subsequently transported via 
nuclear pores to the nucleus. The binding of cortisol to GR can be regulated within the cell 
by 11β-hydroxysteroid dehydrogenases (11β-HSDs). Cortisol can be oxidized into its 
inactive form, cortisone, by 11β-HSD2, while 11β-HSD1 converts cortisone back to cortisol. 
This mechanism ensures the proper availability of cortisol in the cells. Dysregulation of 
either form of the 11β-HSD protein can lead to severe defects in the endogenous action of 
GR (Seckl 2004, Chapman et al. 2013). 
In the nucleus, GR forms a homodimer through its second zinc finger and binds to 
GREs in the regulatory regions of its target genes. The GRE is an imperfect palindrome 
sequence that consists of two 6 bp half-sites separated by three nucleotides, 5’-
RGnACAnnnTGTnCY-3’, where n is any base, R is purine (A or G) and Y is pyrimidine (C 
or T) (Aranda & Pascual 2001, Heitzer et al. 2007, Oakley & Cidlowski 2013). The sequence 
for GRE, discovered already over 30 years ago, was shown to mediate hormone 
responsiveness (Chandler et al. 1983, Payvar et al. 1983). Interestingly, in line with the 
secretion of glucocorticoids in a circadian rhythm, the binding of GR to GRE occurs in 
dynamic pulses rather than being static in the chromatin (George et al. 2009, Stavreva et al. 
2009). Furthermore, this fact is also reflected at the level of gene expression, as GR target 
genes are expressed at alternating activation and repression phases (John et al. 2009). In the 
chromatin, GR influences transcription by recruiting coregulators and by influencing the 
action of other TFs, for example via tethering mechanisms (Oakley & Cidlowski 2013) (Fig. 
4). Repression of transcription via tethering is generally termed as transrepression. The 
transcriptional regulation by GR can roughly be divided into three categories: direct, 
tethering and composite regulation (Fig. 4). The non-genomic actions of GR have been 
reviewed elsewhere (Groeneweg et al. 2012, Samarasinghe et al. 2012). 
 GR recruits different coregulators in a sequential process that influences chromatin 
accessibility and PolII activity. In hormone-dependent gene activation, GR, like other SRs, 
recruit mainly coactivators of the SRC family, such as GR interacting protein -1 (GRIP1) 
(Voegel et al. 1996, Heitzer et al. 2007, Chinenov et al. 2012) and CBP/p300 coactivators. 
There is little known about the recruitment of corepressors by GR, mainly due to the fact 
that GR-mediated gene repression was previously thought to occur via GR’s ability to 
inhibit the action of other TFs (Busillo & Cidlowski 2013). In addition to recruitment of 
HAT activity containing coactivators, GR can interact through its LxxLL motifs in the LBD 
with components of the mediator complex (Chen & Roeder 2007). Furthermore, this 
interaction is needed for the GR-mediated gene expression of certain target genes, 
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suggesting the importance of mediating signals from GR to PolII via the mediator complex. 
In light of this fact, GR is able to mediate long-range interactions via the formation of 
chromatin loops (Hakim et al. 2009). 
 There is an extensive interaction between GR and chromatin-remodeling complexes, 
which influences chromatin binding of GR (George et al. 2009). There are both pre-existing 
and hormone/ SWI/SNF-induced sites accessible for GR binding in the genome (John et al. 
2008). Early-response genes harbor GR binding sites at open chromatin regions, while a 
large number of late-response genes need chromatin remodeling before there can be GR 
binding (Reddy et al. 2012). Interestingly, most of the GR binding occurs in the pre-existing 
sites that have cell-specific differences, suggesting that pre-existing chromatin accessibility 
determines the response of the cell to glucocorticoid exposure (John et al. 2011). 
Maintenance of the cell-type specific chromatin accessibility for GR occurs through 
activator protein 1 (AP1) in murine mammary cells (Biddie et al. 2011), and through the 
CCAAT-enhancer binding protein β (C/EBPβ) in mouse livers (Grøntved et al. 2013).  
 
 
 
Figure 4. A schematic presentation of GR action in the regulation of transcription. Cav1, a 
scaffolding protein; NPC, nuclear pore complex; BTM, basal transcription machinery; PI3K, 
phosphoinositide-3-kinase; AKT, protein kinase B. (Reprinted from Oakley & Cidlowski 2013 
with permission of Elsevier.)  
 
The GR’s capabilities to inhibit the action of major pro-inflammatory TFs, AP1 (Yang-
Yen et al. 1990) and NF-κB (Nissen & Yamamoto 2000) are thought to underpin the anti-
inflammatory and immunosuppressive effects of glucocorticoids (Fig. 4). In addition, GR 
can also influence the action of STAT proteins (Rogatsky & Ivashkiv 2006) (Fig. 4). Whereas 
GR represses the action of AP1 and NF-κB and vice versa, the tethering of STAT3 to GR and 
their composite binding to DNA, interestingly, results in transcriptional synergism rather 
than repression of either process (Langlais et al. 2012). 
AP1, that consist of FOS (c-Fos, Fos B, Fra-1, -2) and JUN (c-, v-Jun, Jun B, -D) subunits 
(De Bosscher et al. 2003, Busillo & Cidlowski 2013), is activated by MAPK pathway in 
response to inflammatory stimulus, such as lipopolysaccharide (LPS) and tumor necrosis 
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factor α (TNFα) (Smoak & Cidlowski 2004, Newton & Dixit 2012). GR represses the AP1 
function by directly interacting with c-Jun subunit of the AP1 (Schüle et al. 1990) (Fig. 5). 
Furthermore, the inhibition does not seem to be a result of competition of coactivators 
between GR and AP1 (De Bosscher et al. 2001). In addition, GR can repress the function of 
AP1 in composite binding sites (Malkoski & Dorin 1999). 
 
 
 
Figure 5. A schematic presentation of GR-mediated repression of inflammatory AP1 signaling. 
MEKK3/MKK4, components of MAPK pathway; JLP, scaffolding protein. (Reprinted from Busillo & 
Cidlowski 2013 with permission of Elsevier.) 
 
NF-κB consists of p65 (RelA) and p50 (NF-κB1) subunits (De Bosscher et al. 2003, 
Busillo & Cidlowski 2013) and it is essentially activated via the same inflammatory stimuli 
as AP1 (Smoak & Cidlowski 2004, Pasparakis 2009, Newton & Dixit 2012). In addition to 
LPS and TNFα, NF-κB is also activated by antigen receptors and genotoxic stress, such as 
UV-radiation and reactive oxygen species (ROS) (Oeckinghaus & Ghosh 2009). Prior to the 
arrival of the stimulus, the NF-κB exists in an inactive state residing in a complex with 
members of the inhibitor of NF-κB (IκB) family, such as IκBα. If there is a pro-inflammatory 
stimulus, IκB kinase (IKK) complex phosphorylates IκB that leads to polyubiquitination 
and proteasomal degradation of IκB and activation of NF-κB (Zandi et al. 1997, Mercurio et 
al. 1997, Pasparakis 2009, Oeckinghaus & Ghosh 2009). Compared to repression of AP1, the 
mechanisms of NF-κB repression by GR have been more extensively studied (Fig. 6). 
Similar to AP1, GR can physically interact through its C-terminal zinc finger with the p65 
subunit of NF-κB and repress its activity (Liden et al. 1997). However, in comparison to 
AP1, GR and NF-κB can compete with each other from coactivator CBP/p300 recruitment 
(McKay & Cidlowski 2000). Additionally, GR is able to recruit HDAC2 to NF-κB-regulated 
promoters (Ito et al. 2000). This indicates that GR represses the activity of NF-κB via both 
coregulator recruitment and direct interference. Furthermore, GR can inhibit the 
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inflammatory complex formation between p65 and members of the interferon regulatory 
factor (IRF), such as IRF3 (Ogawa et al. 2005). This inhibition might be attributable to the 
recruitment of GRIP1 by GR to promoters of NF-κB target genes (Chinenov et al. 2012, 
Uhlenhaut et al. 2013). Interestingly, also the tumor suppressor p53 has been shown to 
repress NF-κB signaling in conjunction with GR, evidence of a highly interesting cross-talk 
in the suppression of inflammation in tumors (Murphy et al. 2011). In addition to 
interference with different coregulators, GR can repress the action of NF-κB by inhibiting 
the action of PolII. This occurs through GR’s ability to block the recruitment of positive 
transcription elongation factor P-TEFb that is a CDK capable of phosphorylating the CTD of 
PolII (Nissen & Yamamoto 2000, Luecke & Yamamoto 2005). GR is also able to halt PolII 
elongation at NF-κB target genes (Gupte et al. 2013), which occurs through recruitment of 
negative elongation factor (NEFL) complex that prevents PolII’s entry for elongation.   
 
 
 
Figure 6. A schematic presentation of GR-mediated repression of inflammatory NF-κB signaling. 
(Reprinted from Busillo & Cidlowski 2013 with permission of Elsevier.) 
 
In addition to direct inhibition, GR can repress the action of AP1 and NF-κB via 
indirect mechanisms that rely on the induction of anti-inflammatory genes. GR can induce 
the expression of dual specificity phosphatase 1 (DUSP1), a.k.a MAPK phosphatase 1 
(MKP-1), which inactivates MAPK signaling by dephosphorylating mainly JNK and p38 of 
the MAPK pathway (Smoak & Cidlowski 2004, Clark 2007, Clark & Belvisi 2012). In 
addition, GR can force NF-κB to remain inactive by inducing the expression of NF-κB 
inhibitor α (NFKBIA) that encodes the IκBα protein (Smoak & Cidlowski 2004, Clark 2007). 
Interestingly, the loss of GRIP1 does not influence to the expression of DUSP1 and NFKBIA 
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(Chinenov et al. 2012), indicating a possible backup mechanism that ensures at least partial 
inhibition of AP1 and NF-κB by GR. 
A recent finding also suggests the existence of negative GREs (nGREs) (Surjit et al. 
2011) which consist of 5’-CTCCn[0-2]GGAGCA-3’ consensus sequence (Hudson et al. 2013). 
Through these sites, GR may repress the gene expression by recruitment of corepressor 
complexes independent of tethering (Surjit et al. 2011). Since the three spacing nucleotides 
are required for proper GR homodimer binding (Luisi et al. 1991), GR may bind to the 
nGRE as two separate monomeric units (Hudson et al. 2013). The precise mechanism of 
corepressor recruitment to nGREs remains to be elucidated, as monomeric GR is not 
capable of recruiting corepressors (Hudson et al. 2013). Interestingly, a recent genome-wide 
study indicated that GR mediates activation and repression predominantly from classical 
GREs that are in close proximity to AP1 and NF-κB binding sites. Furthermore, according 
to the study only 20% of the GR-mediated repression of genes occurred through nGREs or 
via a tethering mechanism (Uhlenhaut et al. 2013). 
The glucocorticoids are also used for the treatment of hematological malignancies, in 
addition to inflammatory control. This is due to the fact that glucocorticoids are able to 
induce apoptosis of the hematopoietic cells, such as monocytes, macrophages, as well as T 
and B lymphocytes (Frankfurt & Rosen 2004, Herr & Pfitzenmaier 2006, Viegas et al. 2008). 
B lymphocytes express more GR in spleen and bone marrow, and are more sensitive to dex-
induced apoptosis during short-term glucocorticoid exposure than non-B lymphocyte cells 
(Gruver-Yates et al. 2014). Apoptosis is mainly induced by GR-dependent expression of B-
cell lymphoma/leukemia-2 (Bcl-2) family members, such as bcl-X, that are involved in the 
regulation of apoptosis (Frankfurt & Rosen 2004, Viegas et al. 2008). Interestingly, while all 
the translational isoforms of GR were able of suppressing cytokine and NF-κB signaling, 
cells expressing GR-D3 isoform that lacks the AF-1, were insensitive to glucocorticoid-
induced apoptosis (Wu et al. 2013). Lymphocytes have also been shown to harbor 
glucocorticoid-inducible microRNAs (miRNAs), which contribute to dex-induced apoptosis 
(Smith et al. 2013). Furthermore, the apoptosis can also be induced through the repression 
of NF-κB signaling (Frankfurt & Rosen 2004). 
In addition to apoptosis, glucocorticoids can induce the arrest of cell cycle progression 
by GR-mediated induction of CDK inhibitors (CDKN), such as p21 (CDKN1A), p27 
(CDKN1B), and p57 (CDKN1C) (Rogatsky et al. 1997, Samuelsson et al. 1999, Alheim et al. 
2003). These CDKNs inhibit the progression of cells from G1-S phase to G2-M phase of the 
cell cycle by repressing the action of CDK2, -4 and -6. In conclusion, when glucocorticoids 
are used as drugs they exert various beneficial roles in humans, in addition to the effects 
reviewed in this chapter (Quax et al. 2013, Oakley & Cidlowski 2013, Kadmiel & Cidlowski 
2013, Oakley et al. 2013). However, glucocorticoids also have unfavorable effects, leading to 
serious abnormalities, such as osteoporosis, obesity and cardiovascular disease (Kadmiel & 
Cidlowski 2013). For this reason, there is a need for better understanding on the action of 
GR in order to develop more efficient GR modulators mediating more specifically the 
beneficial effects of glucocorticoids. One such potential modulator is the non-steroidal 
Compound A that retains the repressive capabilities of GR towards NF-κB, but is incapable 
of inducing GR-mediated repression of AP1 and GRE-mediated transcription (Beck et al. 
2013, De Bosscher et al. 2014).  
2.3 GENOME-WIDE APPROACHES TO STUDY TRANSCRIPTIONAL 
REGULATION 
Almost all aspects of molecular biology and biomedicine were revolutionized with the 
introduction of genome-wide methods to study gene expression and to detect single 
nucleotide polymorphisms (SNPs). This started with the development of cDNA 
microarrays (Maskos & Southern 1992, Ramsay 1998, Selinger et al. 2000), followed by the 
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appearance of sequencing, especially next-generation sequencing (NGS) techniques (Soon et 
al. 2013). Microarrays involve the hybridization of a labeled sample (DNA, RNA or cDNA) 
to glass plates, which contain immobilized oligonucleotide probes from desired target 
sequences (Maskos & Southern 1992, Duggan et al. 1999, Hoheisel 2006). Target sequences 
can be customized, ranging from target gene promoters or known human SNPs to exons 
representing all the genes from certain species. The complementary binding of the labeled 
sample to the probes can be measured from the microarray and translated into numerical 
values. Subsequently these values are used in the evaluation of many biochemical 
properties, e.g. changes in gene expression (Watson et al. 1998, Butte 2002, Bertone et al. 
2005, Hoheisel 2006, Gresham et al. 2008). 
In principle, there are two types of approaches to study “transcriptional” gene 
regulation by microarrays; expression (cDNA/RNA) microarrays and chromatin 
immunoprecipitation (ChIP) coupled to microarrays (ChIP-chip) (Duggan et al. 1999, Ren et 
al. 2000, Shannon & Rao 2002, Hoheisel 2006). Probes in expression microarrays usually 
represent at least one representative exon of each gene (Hoheisel 2006), and in ChIP-chip, 
they can represent any genomic area ranging from regions surrounding target genes (So et 
al. 2007, Bolton et al. 2007) and whole chromosomes (Wang et al. 2007) to full-genomes 
(Kolasinska-Zwierz et al. 2009). Since full-genome analysis of human genome by ChIP-chip 
requires multiple microarrays, ChIP coupled to massive parallel sequencing (ChIP-seq) has 
replaced this technique entirely as it is more cost-effective (Park 2009). Furthermore, the 
ChIP-chip signal is saturated at highly occupied region, and the resolution of the signal-to-
noise ratio is far superior in ChIP-seq (Gilchrist et al. 2009, Park 2009). Although ChIP-seq 
has replaced ChIP-chip, expression profiling by microarrays is still quite widely used e.g. 
for biomarker and disease-subclass determination, and it has not yet been replaced 
completely by RNA sequencing (RNA-seq). This is due to the fact that the bioinformatic 
analysis of microarray data is much more standardized and straightforward than RNA-seq 
data (Young 2000, Brazma et al. 2001, Butte 2002, Hoheisel 2006). Furthermore, while there 
is poor reproducibility of data between ChIP-seq and –chip (Ho et al. 2011), the data 
obtained from expression microarray and RNA-seq do seem to complement each other 
(Malone & Oliver 2011). In addition, alternative microarray technologies, e.g. bead arrays, 
have further helped to keep this technology alive (Oliphant et al. 2002, Fan et al. 2005, 
Steemers & Gunderson 2007). However, RNA-seq most likely replaces microarrays rapidly 
in short-period of time. 
2.3.1 Next-generation sequencing techniques 
It is estimated that the cost of the initial sequencing of the human genome was around 2.7 
billion USD (Lander et al. 2001, Pareek et al. 2011). The sequencing was performed by 
capillary sequencing based on Sanger sequencing (Sanger 1975, Sanger et al. 1977). Within 
ten years from the sequencing of the human genome, the NGS techniques that enable the 
sequencing of millions of nucleotides simultaneously by a high number of parallel 
processes, became available to all researchers (Pareek et al. 2011, Soon et al. 2013). By using 
NGS technique, the cost of the sequencing of human genome has been reduced significantly 
to 4 008 USD in January 2014, with the cost decreasing every year (Pareek et al. 2011, 
https://genome.gov/). Furthermore, it would take several hundred Sanger-based capillary 
sequencers to generate the same amount of the data that one NGS instrument can produce 
in 24 h (Schuster 2008). 
The major NGS instruments are provided by four different companies (Roche, 
Applied Biosystems, Illumina, and Pacific Biosciences) that utilize different sequencing 
strategies, ranging from emulsion PCR and Bridge/solid-phase library amplification to 
polymerase-based sequencing-by-synthesis/reversible terminators and real-time 
sequencing chemistry (Metzker 2005, Mardis 2008, Metzker 2010, Pareek et al. 2011, 
Niedringhaus et al. 2011). All the NGS instruments can be utilized for investigating 
transcriptional regulation. With these various different applications, it is possible to obtain 
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information ranging from the organization of chromatin structure to determining changes 
in gene expression. The most widely used applications for examining the regulation of 
transcription at a genome-wide level are reviewed in the following section. 
2.3.1.1 RNA-seq 
As stated, microarrays were extensively used in transcriptome profiling prior to the 
development of NGS techniques. While microarrays rely on the hybridization of the sample 
to probe, in RNA-seq the actual cDNA sequences of the sample are determined. The RNA 
sample in RNA-seq is usually converted to cDNA fragments that are subsequently 
sequenced. The cDNA can be sequenced either from one end (single-end sequencing) or 
from both ends (paired-end sequencing), a technique which improves the quality and 
mapping of the results. One sequenced DNA fragment is called a read and the typical read 
length for RNA-seq is 30 – 400 bp representing either an exonic, a poly(A) end or an exon-
junction read (Wang et al. 2009, McGettigan 2013). While both microarrays and RNA-seq 
can quantify gene expression levels, only RNA-seq can be reliably used to detect different 
gene isoforms and allele-specific expression. Furthermore, the sensitivity in microarrays for 
low and very high expressed genes is very poor as compared to RNA-seq which in some 
respects has no limits (Marioni et al. 2008, Nagalakshmi et al. 2008, Wang et al. 2009, Soon et 
al. 2013). In addition, qPCR data correlates better with RNA-seq than with expression 
microarray data (Nagalakshmi et al. 2008). 
The major challenge of RNA-seq is the bioinformatic analyses in addition to technical 
issues, such as library preparation. While the microarrays have more standardized data 
analysis (Brazma et al. 2001), RNA-seq, being quite new technology, has not yet adopted 
any specific guidelines (Wang et al. 2009, McGettigan 2013). However, the ENCODE project 
consortium is continuously forming the guidelines for RNA-seq experiments 
(https://genome.ucsc.edu/ENCODE/experiment_guidelines.html), but they are quite open, 
as the required replicate number is currently two, whereas for microarrays it is at least 
three. One challenge is also that whereas the microarray data analyses are predominantly 
done in the R environment (http://www.r-project.org/) with Bioconductor packages 
(Gentleman et al. 2004, http://www.bioconductor.org/), analysis of RNA-seq data can and is 
performed with multiple different programs (Wang et al. 2009, Garber et al. 2011). Despite 
the multitude of programs in RNA-seq data analysis, artifacts and bias factors still exist 
(McGettigan 2013), indicating that further development is needed in RNA-seq 
bioinformatics. 
2.3.1.2 GRO-seq 
One of the newest NGS technique developed to study transcriptional regulation is global 
run-on sequencing (GRO-seq) (Core et al. 2008). GRO-seq measures the production of 
nascent RNA, which enables not only the detection of PolII-bound transcripts, but also the 
direction of transcription and the decay rate of the transcript (Core et al. 2008, Soon et al. 
2013). In GRO-seq, once the nuclei have been isolated, the new initiation of transcription by 
PolII is restricted by anionic detergent sarkosyl, which inhibits the preinitiation complex 
formation and the initiation of transcription (Dvir 2002, Core et al. 2008). In subsequent run-
on reactions, transcriptionally engaged PolIIs have an excess amount of dATP and dGTP, a 
limited amount of dCTP, and 5-bromouridine 5’-triphosphate (BrUTP), which results into 
BrUTP incorporation to nascent RNA. After RNA extraction, nascent RNAs can be isolated 
via anti-BrUTP beads and subjected to RNA-seq (Core et al. 2008). Interestingly, GRO-seq 
could identify over two times more active genes than microarray (Core et al. 2008). 
GRO-seq can also be utilized to measure PolII transcription dynamics. The 
transcription rate was the slowest near the promoter region, and it increased during 
transcription with the density of PolII at gene body, correlating to elongation rate (Danko et 
al. 2013). In addition, different stimuli can have varying effect to transcription rates, 
estradiol treatment increased the initiation rate of PolII, and TNFα treatment influenced 
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mainly paused PolIIs (Danko et al. 2013). With regard to estradiol treatment and ER 
activation, the RNA generated at enhancers (enhancer RNA, eRNA) involved in the 
enhancer activity and stabilization of enhancer-promoter looping (Wang et al. 2011, Li et al. 
2013, Lam et al. 2013, Kaikkonen et al. 2013a), represent active ER binding sites (Hah et al. 
2013). Furthermore, they can also be used in the de novo prediction of enhancers (Hah et al. 
2013).  
Although, RNA-seq is a useful tool in the study of gene expression, the amount of 
information obtained from GRO-seq is far superior to RNA-seq. However, the limiting 
factor in GRO-seq is the isolation of nascent RNA, which is not trivial. In the best-case 
scenario, RNA-and GRO-seq data complement each other. 
2.3.1.3 ChIP-seq 
ChIP is a method that can be used to map the occupancy of TFs, coregulators or histone 
modifications in vivo across the genome via cross-linkage of protein-DNA interactions 
(Gilmour & Lis 1984, Gilmour & Lis 1985, Solomon et al. 1988). After cross-linking, the 
chromatin is fragmented by sonication, and the protein/modification of interest is enriched 
by immunoprecipitation. In ChIP-seq, the enriched DNA, e.g. representing the binding sites 
of TF, is subjected to NGS (Fig. 7a) (Johnson et al. 2007, Massie & Mills 2008, Kharchenko et 
al. 2008, Park 2009, Maston et al. 2012). Interestingly, the majority of ChIP-seq experiments, 
including the work done by the ENCODE project consortium 
(http://encodeproject.org/ENCODE/index.html) is conducted on the Illumina platform. As 
mentioned earlier, the resolution of ChIP-seq signal is excellent, with average read length of 
35 – 50 bp (Park 2009, Furey 2012). While paired-end sequencing is regularly used for RNA-
seq, traditionally ChIP-seq has been done by single-end sequencing. However, it has been 
shown that paired-end sequencing of ChIP-seq samples increases the sequencing depth and 
accuracy of the read alignment to that of repetitive sequences (Chen et al. 2012). 
Interestingly, while cross-linking of DNA-protein interactions is one hallmark of ChIP, TFs 
binding can also be mapped in a genome-wide manner from native chromatin (Kasinathan 
et al. 2014). This method relies on micrococcal nuclease-digestion of non-cross-linked 
chromatin, followed by affinity purification of TFs and paired-end sequencing. 
Apart from technical issues in ChIP, the major challenges in ChIP-seq are the 
bioinformatic analyses (Park 2009, Furey 2012). In comparison to RNA-seq, the ENCODE 
project consortium has issued more detailed guidelines for ChIP-seq experiments (Furey 
2012). For mammalian genomes, the objective is to obtain over 10 million uniquely 
mapping reads, with the sequencing depth of the control at the same level. In addition, two 
biological replicate samples is the minimum, which should have either at least 75% peak 
overlap or at least 80% peak overlap of the top 40% peaks. If these requirements are not 
met, then a third replicate is necessary (Furey 2012, Landt et al. 2012). In addition, ENCODE 
recommend the use of irreproducible discovery rate (IDR) to compare ChIP-seq replicates 
(https://sites.google.com/site/anshulkundaje/projects/idr).  
2.3.1.4 Modifications of ChIP-seq 
Due to the fact that ChIP is the best tool for investigating the binding of proteins to DNA, 
multiple modifications to the method have been developed recently. Modified ChIP 
methods can improve cost effectiveness and sensitivity (Garber et al. 2012, Blecher-Gonen et 
al. 2013), as well as the signal resolution (Rhee & Pugh 2011, Rhee & Pugh 2012a) of ChIP. 
The recently developed high-throughput ChIP (HT-ChIP) allows fully automated ChIP-seq, 
which enables large-scale TF or histone modification screens (Blecher-Gonen et al. 2013). 
This technique uses solid phase magnetic beads for immunoprecipitation, DNA 
purification, size-selection, and library construction. In addition, all the reactions are 
performed in the same 96-well, reducing the required starting material and keeping the 
sample loss to a minimum. Single HT-ChIP with 25 TFs and 4 histone modifications in four 
different time-points, resulted in over 180 000 TF-DNA interactions, showing a 
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multilayered TF network with three major layers; generation of accessible chromatin by 
pioneer factor binding, priming of lineage-specific genes by second tier of TF binding, and 
activation of genes with shared biological processes by TF binding in a dynamic fashion 
(Garber et al. 2012). 
 
 
 
Figure 7. NGS techniques to study transcriptional regulation. (a) TF binding, ChIP-seq. (b,c) 
Open chromatin regions, DNase-seq (b) and FAIRE (c). (d,e) 3D organization of chromatin and 
long-range interaction, Hi-C (d) and ChIA-PET (e). (f) Evolutionary conserved TF binding sites. 
(Reprinted from Maston et al. 2012 with permission of Annual Reviews.) 
 
Even though the resolution of ChIP-seq signal is excellent, ChIP coupled with 
exonuclease (ChIP-exo) trim can result in resolution down to the level of a single base-pair 
(Rhee & Pugh 2011). In ChIP-exo, the immunoprecipitated sample is subjected to 5’-3’ 
degradation by λ exonuclease treatment. The cross-linked protein protects the DNA from 
the exonuclease, thereby resulting in the production of 5’-fragments that are at a fixed 
distance from the bound protein (Rhee & Pugh 2011, Rhee & Pugh 2012a). The binding sites 
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of the protein can be detected with high-resolution by sequencing these 25 – 50 nucleotide 
fragments. Furthermore, the signal-to-noise ratio is many hundred times higher than can be 
achieved with ChIP-seq (Rhee & Pugh 2011, Rhee & Pugh 2012a, Rhee & Pugh 2012b). In 
addition, ChIP-exo can give more precise information of the nature of the ChIP peaks, such 
as the number of binding motifs, the occurrence and the nature of the adjacent motifs 
(Serandour et al. 2013). However, the optimization and other technical issues inherent in 
ChIP-exo as well as in HT-ChIP, do limit the use of these highly informatic methods.  
As with RNA-seq, the ChIP-seq data analysis can also be performed with multiple 
different programs (Gilchrist et al. 2009, Pepke et al. 2009, Kim et al. 2011). The data analysis 
utilized by our laboratory will be reviewed in the section 2.3.2. 
2.3.1.5 DNase-seq 
Although ChIP is an excellent research tool e.g. in the study of TF binding, the availability 
and functionality of the antibody limits its use. Easier and cheaper way to assess gene 
regulation and potential TF binding to DNA is to study open chromatin regions that 
represent cis-regulatory elements such as enhancers, promoters, insulators, silencers and 
locus control regions (Thurman et al. 2012, Maston et al. 2012). Open chromatin regions can 
be mapped by traditional DNase I digestion (Keene et al. 1981, McGhee et al. 1981) (Fig. 7b), 
or by a newer technique called formaldehyde-assisted isolation of regulatory elements 
(FAIRE, Giresi et al. 2007) (Fig. 7c). 
Initially, DNase I hypersensitive sites (DHSs) were found over 30 years ago (Keene et 
al. 1981, McGhee et al. 1981); in these locations the nucleosome-depleted genomic regulatory 
regions are prone to DNase I digestion. In comparison, DNA is protected from digestion if 
it is present in tightly packed nucleosomes and other high-order chromatin structures. 
Mapping of DHSs also changed by NGS techniques and the development of DNase-seq, 
where DNase I digested DNA fragments are sequenced from the ends to discover the DHSs 
(Song & Crawford 2010). The data generated by DNase-seq are highly similar to ChIP-seq, 
however, while ChIP-seq data represent binding sites of a single TF, data from DNase-seq 
represent binding of several TFs to open chromatin regions (Thurman et al. 2012). In 
addition, the number of open chromatin sites/peaks identified is far larger than peaks 
identified in ChIP-seq. Interestingly, most of the DHSs are cell-type specific, especially in 
the gene body and intergenic sites, indicating that differential TFs binding between cell 
lines could contribute to their function (Thurman et al. 2012, Natarajan et al. 2012). 
Furthermore, the open chromatin region can be used to predict cell-type-specific gene 
expression (Natarajan et al. 2012). In addition, the most highly expressed genes are likely to 
have DHS in their upstream region from TSS, reflecting the fact that active genes are 
associated with open chromatin (euchromatin) regions (Boyle et al. 2008). 
2.3.1.6 FAIRE-seq  
In comparison to DHS mapping, FAIRE uses basic principles in ChIP method to map open 
chromatin regions. In FAIRE, cells are cross-linked as in the ChIP technique, however, 
rather than immunoprecipitating protein-DNA complexes with antibody, the sonicated 
sample is subjected to phenol/chloroform extraction. During the extraction phase, the open 
chromatin regions that are nucleosome-free remain in the aqueous phase, whereas cross-
linked protein-DNA complexes are sequestered in the organic phase. The open chromatin 
region with TF binding, remain in the aqueous phase due to the fact that TFs has far fewer 
potential cross-linking sites compared to histones. Subsequently, the DNA in the aqueous 
phase is extracted and subjected to NGS (FAIRE-seq) (Giresi et al. 2007, Giresi & Lieb 2009, 
Simon et al. 2012). Essentially, FAIRE-seq can identify similar open chromatin regions as 
DNase-seq. Furthermore, regions identified by FAIRE-seq are also likely to be found at the 
most highly expressed genes (Gaulton et al. 2010). In addition, the combination of DNase-
seq and FAIRE-seq is more efficient in the identification of open chromatin regions than 
either technique alone (Song et al. 2011). 
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Although DNase-seq is straightforward and inexpensive to perform, recently it has 
been shown to contain some intrinsic biases. While no DNase I cutting bias was found at 
CTCF sites, a highly similar DHS profile was seen between sites that actually bind, and sites 
that confidently do not bind AR and p53 (He et al. 2014). This indicates, that the TF binding 
sites can arise from DNase I cutting bias rather than from actual protein-DNA interactions. 
To resolve this bias, DNase-seq should be performed hand in hand with ChIP-seq, in order 
to obtain more reliable results. 
2.3.1.7 Hi-C 
As discussed earlier, most of the binding sites of NRs, including GR, reside far away from 
the target genes TSS in the intronic and intergenic regions (Welboren et al. 2009, Yu et al. 
2010, John et al. 2011, Uhlenhaut et al. 2013, Ding et al. 2013). Furthermore, as mentioned, 
GR is capable of mediating long-range interactions via the formation of chromatin loops 
(Hakim et al. 2009). The initial method which was utilized to study these chromatin loops is 
called chromosome conformation capture (3C) that uses restriction enzyme digestion and 
ligation to merge interacting chromatin parts together (Dekker et al. 2002). In the last ten 
years, 3C method developed quickly into two forms, circularized 3C (4C, Simonis et al. 
2006) and carbon-copy 3C (5C, Dostie & Dekker 2007) methods that utilize microarrays and 
subsequently NGS which allows mapping of several chromatin interactions (de Wit & de 
Laat 2012, Lan et al. 2012a, Sanyal et al. 2012). Ultimately, the development of 3C resulted in 
the creation of two similar techniques called genome-wide 3C (Hi-C) (Lieberman-Aiden et 
al. 2009) (Fig. 7d) and chromatin interaction analysis by paired-end tag sequencing (ChIA-
PET) (Fullwood et al. 2009a) (Fig. 7e) that make it possible to identify all chromatin 
interactions (de Wit & de Laat 2012, Maston et al. 2012).    
The chromatin interactions in Hi-C are enriched by using biotin. After cross-linking 
and restriction enzyme digestion, the ends of the interacting DNA fragments are filled with 
biotin. Once the biotinylated ends are ligated together and cross-linking is reversed, the 
interacting DNA fragments are enriched with biotin pull-down, and sequenced by paired-
end sequencing from both interacting DNA fragments (Lieberman-Aiden et al. 2009, Belton 
et al. 2012). This enables the discovery of all DNA-DNA interactions. Hi-C can identify over 
one million chromatin interactions (Jin et al. 2013), and it can be conducted at a single-cell 
resolution (Nagano et al. 2013). Furthermore, combination of Hi-C and ChIP-seq shows that 
Hi-C can identify interacting loci that are biologically relevant (Lan et al. 2012b). 
2.3.1.8 ChIA-PET 
Technically the Hi-C and ChIA-PET are rather similar, however, while Hi-C is used to map 
all DNA-DNA interactions, ChIA-PET can be used to investigate all the TF-DNA 
interactions. This difference originates from the DNA fragment enrichment; ChIA-PET uses 
ChIP-based antibody enrichment of target protein interactions, instead of biotin pull-down 
of all interactions (Fullwood et al. 2009a, Fullwood et al. 2009b). The identified number of 
interactions is notable smaller in ChIA-PET than in Hi-C, reflecting its similarity to ChIP-
seq (Zhang et al. 2013). The integration of ChIP-seq data with ChIA-PET data can be more 
useful than integration with Hi-C, as the interacting factor is known in ChIA-PET. The 
combination of ChIP-seq, DNase-seq and ChIA-PET has been used to map mouse 
enhancer-promoter interactions (Kieffer-Kwon et al. 2013). Interestingly, the creation of cell-
type-specific patterns of gene expression is not restricted to open chromatin regions 
(Natarajan et al. 2012, Rivera & Ren 2013, Voss & Hager 2014), as enhancer usage also 
differs between cell-types and tissues (Kieffer-Kwon et al. 2013). Furthermore, this is also 
seen for the more common TFs, such as MYC that exhibits entirely different enhancer 
landscape interactions between mouse embryonic stem cells and B lymphocytes. 
It is useful to combine ChIP-seq data with either Hi-C or ChIA-PET data, as most of 
the promoter-enhancer interactions are not located to the nearest TSS (Zhang et al. 2013), 
but the median distance between promoter and enhancer region is around 100 kb (Jin et al. 
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2013). It also seems that the more complex the NGS-based method, the more complex is the 
data analysis (Li et al. 2010b, Zhang et al. 2012, Belton et al. 2012, Stadhouders et al. 2013). 
Furthermore, interaction biases can arise from multiple sources, like from the depth of the 
sequencing (Yaffe & Tanay 2011, Peng et al. 2013). 
2.3.2 Bioinformatics 
The analysis of NGS data is performed mainly on the command line tools (Pepke et al. 2009, 
Barta 2011) and web-based programs, but there are some versions of commercial software 
with a graphical user interface (GUI). However, commercial software development is 
usually considerably behind the developmental progress of freely available tools. 
Depending on the data type, the NGS data analysis can demand an enormous amount of 
computing power. In general, command line tools are used in the initial data analysis, e.g. 
read alignment, to be followed by the downstream data analysis which can be undertaken 
with web-based programs as well as command line tools. The command line NGS analysis 
tools are based on UNIX programs, such as C, C++, PERL and PYTHON (Barta 2011). This 
chapter will focus on the data analysis of ChIP-seq (Fig. 8). 
 
 
 
Figure 8. ChIP-seq analysis pipeline. Bioinformatic analysis of ChIP-seq data starting from raw 
data (yellow boxes) that is aligned to reference genome and subjected to peak finding algorithm 
(blue boxes). Finally, analyses from the aligned reads and peaks are performed with various 
programs and tools (red boxes). Controls and replicates are used to obtain reliable results 
(green boxes).  
 
ChIP-seq data generated by Illumina (HiSeq 2000 system) results in 45 – 50 bp reads. 
Initially, the reads are analyzed by FastQC (Andrews 2012) to assess the quality of the 
reads. The reads are in the FASTQ format, containing four lines of information; 1, unique 
identified; 2, raw sequence; 3, identifier; 4, read quality score. Lines 1 and 2 by themselves 
form the FASTA format. By using the quality score of the reads, FastQC reports the 
confidence range of each read length. The subsequent analysis to peak calling is performed 
27 
 
 
by using semi-automated Shell script in the command line. The Shell script contains all the 
information, e.g. data location, tools and commands, needed to perform the data analysis. 
Initially, all the read lengths are trimmed to 40 bp by FASTX-Toolkit (Hannon 2012) to 
exclude all the low quality reads. In addition, FASTX-Toolkit is used to filter out artifact 
and duplicated reads, wherein the latter case usually arises from the amplification of the 
sequencing library and from the sequenced adapters (Aird et al. 2011). Read duplication can 
influence the data analysis if not removed. Those reads that pass the quality filtering 
protocol, are mapped to the human genome version hg19 by using Bowtie written in C++ 
(Langmead et al. 2009). The Bowtie is faster and more efficient than other read alignment 
software, such as SOAP (Li et al. 2009a) and MAQ (Li & Durbin 2009). The alignment is 
performed with the following parameters: seed length is maximum (40 bp); 1 bp mismatch 
is allowed, but only one and only the best alignment is reported; the results are written in 
the Sequence Alignment/Map (SAM) format. As the SAM format contains the sequence 
alignment data in a tab-delimited text file, it needs to be converted into the equivalent 
binary version of the SAM, Binary Alignment/Map (BAM) format. This is performed, 
because the BAM format is more compacted in size and alignments of specified regions can 
be retrieved faster than with the SAM format. Furthermore, by indexing the BAM file, the 
downstream applications do not need to load the entire file into the memory in order to 
perform the analysis on specific genomic regions (Li et al. 2009b). The generated BAM file 
can be used for visualization of the alignments in the Integrative Genomics Viewer (IGV) 
(Robinson et al. 2011), for downstream analyses, and for peak detection. 
The detection of enriched regions, e.g. peaks, is conducted either with Model-based 
Analysis of ChIP-seq (MACS) written in PYTHON (Zhang et al. 2008b, Feng et al. 2012), or 
with Hypergeometric Optimization of Motif EnRichment (HOMER) written in PERL and 
C++ (Heinz et al. 2010).  There are other ChIP-seq peak detection softwares, such as 
CisGenome (Ji et al. 2008, Pepke et al. 2009, Kim et al. 2011). MACS builds a model peak 
from 1 000 high-quality peaks of the given ChIP-seq data which is subsequently used for 
the peak detection. The peak detection is based on the enrichment of reads to the forward 
and reverse strands, and their calculated center that most likely represents the protein-
DNA interaction site. Both MACS and HOMER programs use sequenced control sample of 
IgG or input as background, which is used to calculate the False Discovery Rate (FDR) and 
the p-values of each peak. Detected peaks are reported in tab-delimited text file, called the 
BED file. The file contains at least three columns; chromosome, start, and end, which 
specifies the peak location and size. Once statistically significant peaks have been detected, 
the peaks are overlapped with a biological replicate sample, where the overlap meets the 
ENCODE requirements (Furey 2012, Landt et al. 2012). Subsequently, the statistically 
significant peaks found in both replicate samples are used in the downstream analyses. 
Downstream analysis tools can be performed with command line and web-based 
tools. Basic overlapping analysis of peaks can be conducted with BEDTools, which is 
written in C++ (Quilan & Hall 2010), however, its use is limited to data manipulation, as 
biological analyses cannot be done with this software. A highly useful command line tool 
for downstream analysis is HOMER (Heinz et al. 2010). In practice this can perform all the 
necessary downstream analyses, such as overlapping peaks, motif enrichment analysis, and 
peak annotation to genomic elements or gene expression data. Another command line tool 
with GUI called seqMINER is useful in clustering of ChIP-seq peaks (Ye et al. 2011). 
However, the clustering in seqMINER can only be conducted with k-means clustering that 
requires a predetermined number of clusters. Hierarchical clustering with no 
predetermined factors can be done in R environment. In addition to command line tools, 
downstream analysis can be performed with Cistrome (Liu et al. 2011), a web-based tool 
that can perform all the necessary ChIP-seq downstream analyses. It was built on top of 
Galaxy (Goecks et al. 2010) which can be also used for mapping of the raw reads to the 
genome. However, it is more efficient to perform alignments with command line tools. 
Finally, the enrichment and pathway analyses can be performed by Ingenuity Pathway 
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Analysis (IPA, http://ingenuity.com/) or by Genomic Regions Enrichment of Annotations 
Tool (GREAT) (McLean et al. 2010), and this latter tool to some extent can also be 
incorporated into the integration of ChIP-seq data with gene expression data. Not only does 
the sequencing technology improve rapidly, so too does the development of analysis tools, 
providing ever greater analytical possibilities for molecular biologists. 
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3 Aims of the Study 
Despite the fact that GR binding had been studied by genome-wide methods, at the 
beginning of this thesis project, more detailed analyses of GR target gene regulation by 
long-range chromatin interactions were largely unavailable. A sensitive glucocorticoid 
biomarker gene FKBP51 was chosen as a model with which to obtain a detailed 
characterization of long-range regulation. In addition, there was no genome-wide 
information of the role of GR SUMOylation in the regulation of the receptor chromatin 
occupancy or target gene expression. During this thesis work, genome-wide ChIP-
sequencing (ChIP-seq) technology became available for use. That method, along with 
genome-wide transcriptome analysis, was utilized to study the effects of SUMOylation on 
GR signaling.    
 
The specific aims of the study were: 
 
 To characterize the long-range chromatin and transcriptional gene regulation of 
FKBP51 locus by GR. 
 
 To reveal the role of GR SUMOylation in target gene regulation on a genome-wide 
scale. 
 
 To study the genome-wide occupancy of GR and SUMO-2/3 on chromatin. 
 
 To uncover the effects of GR SUMOylation on the receptor chromatin binding and 
target gene responses during electrophilic cell stress. 
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4 Materials and Methods 
A wide range of molecular biology methods was utilized in this thesis (Table 1). Detailed 
descriptions of the experimental procedures have been described in the original articles I-
III. In addition, the antibodies used in unpublished ChIP-seq analyses, and the protocol for 
EMSA analyses is shown.  
 
Table 1. Summary of the methods used in this thesis.    
Method Original article 
Cell culture I, II, III 
Generation of cell lines stably expressing GR II 
Construction of plasmids I, II 
Transient transfection assay I 
Reporter gene assay I 
Immunoblotting I, II, III 
Immunoprecipitation II, III 
Biotin pull down assay III 
Cell proliferation assay II 
Fluorescence-activated cell sorting (FACS) II 
Isolation of RNA I, II, III 
Quantitative RT-PCR I, II, III 
RNA interference I, III 
Illumina bead array II, III 
Chromatin immunoprecipitation (ChIP) I, II, III 
Sequential-ChIP (re-ChIP) II 
ChIP coupled with DNA deep sequencing (ChIP-seq) II 
Genome-wide bioinformatics II, III 
 
 
ChIP-seq antibodies 
The antibodies used in unpublished ChIP-seq experiments were as follows: PolII (MMS-
126R) from Covance Inc. (Princeton, NJ, USA), H3K4me2 (ab7766) and PIAS1 (ab77231) 
from Abcam (Cambridge, UK). 
 
Electrophoretic mobility shift assay (EMSA) 
COS-1 cells were transfected with 7.5 μg of HA-wtGR or HA-GR3KR in the presence or 
absence of 7.5 μg of pCMV-myc-SUMO-2 Pro (SUMO-2P) (Owerbach et al. 2005) by using 
TransIT-LT1-transfection reagent (Mirus Bio Corporation, Madison, WI, USA) according to 
manufacturer’s instructions. One hour before lysate extraction, the cells were exposed to 
dex (100 nM), and extracted in protein isolation buffer [20 mM Tris-HCl (pH 7.5), 400 mM 
KCl, 15% (vol/vol) glycerol, 1 mM EDTA, 2 mM dithiothreitol, 100 nM dex, 1:100 diluted 
protease inhibitor cocktail (Sigma-Aldrich)] and analyzed as described (Thompson et al. 
2001). Twelve micrograms of cell extract were incubated with 32P-labeled dsGRE (5’-
TGAACATAGTACGTGATGTTCTCAAGATA-3’). For the antibody complexes, 1 μg of 
antibody was incubated for 30 min with cell extract and dsGRE. The complexes were 
separated on 4% non-denaturing PAGE. The gels were dried, and a phosphoimager 
(FLA3000; Fuji, Tokyo, Japan) was used for visualization. 
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5 Results and Discussion 
5.1 FROM A SINGLE GR TARGET LOCUS TO TARGETS ON WHOLE 
GENOME LEVEL 
Genome-wide binding of GR (Reddy et al. 2009, Rao et al. 2011, John et al. 2011, Uhlenhaut et 
al. 2013) as well as other NRs (Welboren et al. 2009, Yu et al. 2010, Ding et al. 2013) indicates 
that the binding sites of these receptors preferentially reside in the intronic and intergenic 
regions, distal from the TSS. However, more detailed studies on GR target gene regulation 
have concentrated on only a few genes, such as tyrosine aminotransferase (TAT) and 
glucocorticoid-induced leucine zipper (GILZ), which harbor GR binding sites (GRBs) in 
their proximal promoters (Blind & Garabedian 2008). Ten years ago, FK506-binding protein 
51 (FKBP51) was found to be regulated by glucocorticoids via a distal intronic response 
element (Hubler & Scammell 2004); this was subsequently confirmed in a ChIP-chip study 
(So et al. 2007). In addition, the same element regulated AR-mediated gene expression of 
FKBP51 (Makkonen et al. 2009).  
FKBP51 belongs to the protein family of immunophilins that bind 
immunosuppressive drugs and through their tetratricopeptide domain, they participate in 
the protein-protein interactions with HSPs as well as with SRs (Pratt and Toft 1997, Heitzer 
et al. 2007, Kang et al. 2008). Polymorphisms of FKBP51 have been associated with GR 
sensitivity in stress-related psychiatric disorders (Binder 2009). The expression level of 
FKBP51 influences the protein kinase B (AKT) activity in cancer cells affecting the 
effectiveness of chemotherapy (Pei et al. 2009, Li et al. 2011, Wang 2011). Lung biopsies from 
asthmatic patients have indicated that FKBP51 is a sensitive biomarker of corticosteroid 
responsiveness (Woodruff et al. 2007). 
The expression of FKBP51 markedly exceeded that of GILZ in A549 lung cancer cells 
(Fig. 1B in I). While the binding of GR to the FKBP51 locus in A549 cells was analyzed by 
qPCR-based ChIPs (qChIPs), the present GR ChIP-seq results from wild-type GR (wtGR)-
expressing HEK293 cells (wtGR-HEK293 cells; more detailed explanation in section 5.2.1.) 
(Fig. 3A in II) were in good agreement with those obtained with qChIPs (Fig. 5 in I vs. Fig. 
9). PolII ChIP-seq data from the wtGR-HEK293 cells exposed to dex for 1 h indicated 
enrichment of PolII at the FKBP51 gene body of variant 1 after hormone treatment, 
indicating that the FKBP51 had been rapidly and robustly induced by dex (Fig. 9).  Both 
intronic and intergenic enhancers also displayed chromatin occupancy of GR in wtGR-
HEK293 cells similarly to that of GR binding in A549 cells (Fig. 3A in I).  
The distal GRBs that regulated FKBP51 expression were marked with the active 
histone mark H3K4me3 even prior to GR activation in A549 cells (Fig. 5 in I). The same 
distal enhancers in wtGR-HEK293 cells displayed enrichment of the active histone mark 
H3K4me2 in the presence of dex. ENCODE H3K4me3 ChIP-seq data from parental HEK293 
cells without hormone exposure (GSM945288, Thurman et al. 2012) provided evidence of 
enrichment of H3K4me3 merely at the TSSs of FKBP51 variants 1 and 2 (Fig. 9). These data 
suggest that the distal enhancer of FKBP51 locus in wtGR-HEK293 cells is not poised as is 
the case in the A549 cells. However, it is possible that the expression of GR in HEK293 cells, 
is able to reprogram the cells, resulting in a poised enhancer. 
Both CTCF and cohesin are involved in the maintenance of chromatin loops (Wendt et 
al. 2008, Schmidt et al. 2010) and they are thought to participate in the formation of a 
chromatin loop that encompasses the major GRBs in the FKBP51 locus in the A549 cells 
(Fig. 8 in I). The formation of chromatin loop in the FKBP51 locus has been recently 
confirmed by 3C analysis (Klengel et al. 2013). Interestingly, ENCODE CTCF ChIP-seq data 
from parental HEK293 cells (GSM749668, Wang et al. 2012) indicate that also in wtGR-
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HEK293 cells, the major GRBs are bordered by CTCF binding (Fig. 9). It has been also noted 
that the chromatin loops may be pre-existing prior to the appearance of any activating or 
repressing signals (Jin et al. 2013). This suggests that the pre-existing chromatin loop 
encompassing the FKBP51 is independent of cell-type. This concept is further strengthened 
by the fact that the FKBP51 locus is bordered by the CTCF also in VCaP prostate cancer cells 
(Fig 8D in I). 
 
 
 
Figure 9. FKBP51 locus as visualized by genome-wide ChIP-seq data (cf. Fig. 5 in I). Binding of 
GR, SUMO-2/3, PIAS1, PolII and active histone mark H3K4me2 to FKBP51 and ARMC12 
(C6orf81) loci in wtGR-expressing isogenic HEK293 cells. The IgG sample is shown as a control. 
ENCODE H3K4me3 and CTCF ChIP-seq data from parental HEK293 cells are shown as a peak 
track (H3K4me3) or as peak marks (CTCF), indicating the position and the size of the peak. The 
location of the intronic and intergenic enhancers is shown above the tracks.   
 
The FKBP51’s neighboring gene armadillo repeat containing 12 (ARMC12, a.k.a. 
chromosome 6 open read frame 81, C6orf81) was robustly expressed in the VCaP cells but 
not in the A549 cells in response to androgen and glucocorticoid exposure, respectively 
(Fig. 7 in I). The difference was not attributable to differential CTCF binding, but instead it 
was due to the different utilization of a SR-regulated enhancer (Fig. 5A in I vs. Fig. 7F in I). 
The ARMC12 was efficiently expressed in response to dex-treatment in wtGR-HEK293 cells 
(Fig. 1A in III, Fig. 9), and the intergenic enhancer was utilized by GR similarly as the 
intronic region (Fig. 9). It seems that the binding strength of GR to the intergenic site 
dictates the expression of ARMC12 in wtGR-HEK293 cells. Interestingly, the GR ChIP-seq 
of the wtGR-HEK293 cells revealed a cluster of GRBs in the intergenic region of FKBP51 
locus (Fig. 9); this has the characteristics of a super-enhancer (Whyte et al. 2013, Lovén et al. 
2013, Hnisz et al. 2013). High TF and mediator occupied sites that are in close proximity to 
each other are defined as super-enhancers, and their size can be up to 50 kb (Whyte et al. 
2013). Super-enhancers have been proposed to define the biology and identity of the cells 
and function as strong sites for oncogene binding in tumor cells which has an influence on 
tumor pathogenesis (Whyte et al. 2013, Lovén et al. 2013, Hnisz et al. 2013). These data 
suggest that the intergenic binding site in FKBP51 locus might be an important regulatory 
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region in chromosome 6, being involved in long-range glucocorticoid regulation, possibly 
influencing gene regulation by GR in the same chromosome.  
While the present qChIP and ChIP-seq data are in line with each other, the amount of 
data generated by ChIP-seq is far superior to qChIP. Data from ChIP-seq are far more 
accurate in the localization of binding sites, given a complete view of the locus. 
5.1.1 Genome-wide chromatin binding of GR 
GR ChIP-seqs in both cultured cell lines (Reddy et al. 2009, Rao et al. 2011, John et al. 2011) 
and in primary cells (Uhlenhaut et al. 2013) have indicated that the GRBs by and large 
localize to intronic and intergenic sites (Fig. 3B in II) and that the classic GRE is the most 
prevalent motif found in the GRBs (Fig. 3C in II). However, the occurrence of the GRE motif 
in GRBs has varied between studies. The percentage of GRBs that harbor at least one GRE, 
has ranged from 25% (Rao et al. 2011) via 60% (Reddy et al. 2009, Uhlenhaut et al. 2013) up to 
80% (John et al. 2011, Fig. 3B in II). The difference could in part be explained by cell-type 
differences or by the different analysis methods and tools.  
Although almost all GRBs are known to be targeted to pre-existing DHSs (John et al. 
2011), only ~27% of the GRBs in wtGR-HEK293 cells localized to ENCODE DHSs from 
parental HEK293T cells (Supplementary Fig. S11A in II) (GSM1008573, Thurman et al. 2012, 
Natarajan et al. 2012). This might indicate that rather than binding to pre-existing sites, GR 
activation and binding had induced local chromatin remodeling at the GRBs (John et al. 
2008, Biddie et al. 2011, Grøntved et al. 2013). For instance, this phenomenon has been 
observed in mouse liver for the FKBP51 locus, where C/EBPβ binding was assisted by GR-
induced chromatin remodeling (Grøntved et al. 2013). Furthermore, the SWI/SNF 
chromatin-remodeling complex was required for the proper FKBP51 expression (Fig. 6 in I, 
Meijsing et al. 2009). Interestingly, chromatin remodeling induced by GR has been reported 
to assist the binding of other SRs, especially the ER, to the chromatin (Voss et al. 2011, 
Miranda et al. 2013). 
Recently, Uhlenhaut and coworkers examined primary bone marrow-derived 
macrophages to reveal that the GR mediated activation and repression of transcription 
occurs predominantly from classical GREs (Uhlenhaut et al. 2013), rather than by tethering 
mechanisms or from nGREs. Although direct GR binding was more often associated with 
the activation of transcription than with repression (Supplementary Fig. S5A in II, Reddy et 
al. 2009), the GRBs associated with repressed genes showed enrichment of both full and 
GRE half-sites (Fig. 3G in II). The enrichment of half-sites of GREs might be evidence of the 
presence of nGRE, as this has been postulated to contain the characteristics of a half-site 
(Surjit et al. 2011, Hudson et al. 2013). Interestingly, the GREs mediating repression seem to 
reside in close proximity to AP1- and NF-κB-binding sites, and GR and AP1 may co-operate 
if their binding is within the range of one nucleosome (He et al. 2013). However, no such 
binding sites were enriched in the GRBs in the present data (Fig. 3 in II). This may be due to 
the fact that the model cells used here were not exposed to inflammatory stimuli, which 
could have redistributed the GRBs to these kinds of sites. In fact, activation of NF-κB has 
been shown to alter the genome-wide binding pattern of GR in response to an 
inflammatory stimulus (Rao et al. 2011). 
5.1.2 Genome-wide localization of SUMO-2/3 on the chromatin 
Even though proteomic analyses have indicated that there are system-wide SUMOylated 
proteins (Golebiowski et al. 2009, Tatham et al. 2011), very little is known about the genome-
wide occupancy of SUMOs or SUMOylated protein on chromatin and their role in the 
regulation of transcription in different types of cells. However recently, localizations of 
SUMO-1 and SUMO-2/3 were mapped in HeLa, WI38 fibroblasts, BCBL-1 lymphoma, and 
wtGR-HEK293 cells to chromatin (Liu et al. 2012, Neyret-Kahn et al. 2013, Chang et al. 2013, 
Fig. 4A in II). Interestingly, while SUMOylation has been previously linked to 
transcriptional repression (Flotho & Melchior 2013), both SUMO-1 (Liu et al. 2012) and 
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SUMO-2/3 (Neyret-Kahn et al. 2013, Fig. 10) were found at the active chromatin sites rather 
than from inactive chromatin, and with SUMO-2/3 being associated more with 
transcriptional activation rather than repression (Neyret-Kahn et al. 2013, Supplementary 
Fig. S6A in II). SUMO-2/3 also colocalized with the SUMO pathway components, UBC9 and 
PIASy (Neyret-Kahn et al. 2013). Interestingly, almost half of the SUMO-2/3-enriched 
binding sites (SUMOBs) in wtGR-HEK293 cells localized to pre-existing DHSs in parental 
HEK293T cells (Supplementary Fig. S11A in II) (GSM1008573, Thurman et al. 2012, 
Natarajan et al. 2012). 
 
 
 
Figure 10. Glucocorticoid-dependent co-occupancy of SUMO-2/3 and PIAS1 with GR on the 
chromatin. GR, SUMO-2/3 and PIAS1 ChIP-seq peaks were clustered using seqMINER, which 
resulted in three major clusters; GR-induced, stable and non-GR binding sites. The number of 
binding sites in each cluster is shown in the brackets. Data are visualized as heatmap and tag 
enrichment plot.  
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SUMOylated proteins and pathway components were highly enriched at histone 1 
and tRNA gene clusters in WI38 fibroblasts (Neyret-Kahn et al. 2013). This was not a cell-
type dependent phenomenon as the wtGR-HEK293 cells demonstrated similar enrichment 
at these loci (Fig. 11). Interestingly, although SUMO-2/3 binding was enriched at active 
chromatin regions, inhibition of SUMOylation by depletion of the sole E2 conjugase UBC9 
resulted in a robust up-regulation of the histone 1 genes, whereas overexpression of PIASy 
repressed these genes (Neyret-Kahn et al. 2013). This suggests that the SUMOs at these loci 
are linked to repression of gene expression. Furthermore, it is known that many highly 
transcribed genes harbor SUMO-2/3 binding at their promoters (Neyret-Kahn et al. 2013, 
Chang et al. 2013). However, the present data suggest that it is unlikely that SUMOs 
function as negative regulators throughout the genome. Although SUMOBs at the histone 1 
gene cluster displayed similarity between cell lines (Fig. 11), a comparison of genome-wide 
binding patterns of SUMO-2/3 in several cell lines indicated that the majority of the binding 
was cell-type dependent (data not shown). Since SUMO-2/3 was found at active chromatin 
sites, binding of SUMO-2/3 most likely reflected the cell-type-specific gene expression of 
the cells.   
 
 
 
Figure 11. Histone 1 gene cluster as visualized by genome-wide SUMO-2/3 ChIP-seq data in 
wtGR-HEK293 cells exposed to dex. 
 
During activation of GR, a large proportion of GRBs colocalized with SUMOBs (Fig 5A-E 
in II). Furthermore, the SUMOBs displayed the characteristics of GRBs in localization and 
motif enrichment (Fig. 4B-C in II). Interestingly, most of these sites are hormone-dependent, 
i.e. sites where GR activation and chromatin binding are associated with the binding of 
SUMO-2/3 (Fig. 10). Furthermore, PIAS1 binding to the same sites was also GR-inducible. 
The FKBP51 and ARMC12 loci are examples of regions where SUMO-2/3 and PIAS1 bound 
in a hormone-dependent manner (Fig. 9). In addition, UBC9 could bind in a dex-induced 
fashion at least to the intergenic region of the FKBP51 locus (data not shown). Interestingly, 
it is claimed that the SUMO pathway components can together form a ternary complex 
(Mascle et al. 2013). It seems that this complex is capable of binding to chromatin. Whether 
SUMOylation of TFs, such as the GR, occurs prior or after chromatin binding remains to be 
elucidated.  
One fourth of the GRBs overlap with the SUMOBs and PIAS1-binding sites 
irrespective of glucocorticoid treatment (Fig. 10). However, these sites were strongly 
enriched with active H3K4me2 mark, they exhibited lower enrichment of GR ChIP-seq tags 
than the GR-inducible binding sites, and interestingly the SUMO-2/3 ChIP-seq tags 
declined in these sites in response to hormone exposure. Most of these sites are promoter 
sites, where binding of GR replaces SUMOylated proteins from the chromatin. Binding of 
SUMO-2/3 and PIAS1 do not markedly differ in response to hormone outside of GRBs (Fig. 
10). Taken together, these results indicate that activated GR can recruit SUMOylation 
machinery and have a major impact on SUMOylation in chromatin. 
5.2 REGULATION OF GLUCOCORTICOID SIGNALING BY RECEPTOR 
SUMOYLATION 
Global analysis of SUMO-2/3 binding to chromatin emphasizes its active role in 
transcription. However, little is known about how SUMOylation of specific TFs can 
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influence their genome-wide action. Studies investigating a few GR target genes and 
binding sites have indicated that the effect of receptor SUMOylation is target gene-
dependent (Holmstrom et al. 2008, Davies et al. 2008). Coexpression experiments in COS-1 
cells suggested that while PIAS1 could function as a SUMO E3 ligase for GR (Fig. 12A), 
SENP1 deconjugated SUMOs from GR (Fig. 12C). Interestingly, both PIAS1 and SENP1 
acted as GR coactivators in a SUMOylation site-sensitive manner (Fig. 12B and D). 
Previously GR SUMOylation sites have been shown to restrict the transcriptional activity of 
the receptor on simple reporter genes (Fig. 12B and D, Tian et al. 2002, Le Drean et al. 2002). 
This was found also for other SRs, such as AR (Poukka et al. 2000, Rytinki et al. 2012) and 
PR (Knutson et al. 2012). SUMOylation of the PR seems to influence its chromatin binding 
and subsequent coregulator recruitment (Knutson et al. 2012). However, the PR was studied 
in only a few regulatory chromatin regions. SUMOylation could also influence the 
regulation GR’s action during cellular stress, as in the case of the AR (Rytinki et al. 2012).  
 
 
 
Figure 12. PIAS1 and SENP1 can influence both SUMOylation and transcriptional activity of the 
GR. (A) GR and SUMO-1 were coexpressed with or without PIAS1 in COS-1 cells by transfecting 
their cognate expression constructs for 44 h and exposing the cells to dex (100 nM) for 2 h, and 
then the cell extracts were analyzed by immunoblotting with an anti-GR antibody (Kaikkonen et 
al. 2009). (B) Luciferase construct driven by two GREs in front of a TATA box (pGRE2-TATA-
LUC) was cotransfected with wtGR or GR3KR in the absence (-) or presence of PIAS1 (+). After 
24 h, cells were exposed to dex (+) or vehicle (-) for 18 h, and cell lysates analyzed for 
luciferase activity (Makkonen et al. 2011). (C) Essentially the same experiment as in (A), but 
SENP1 was coexpressed instead of PIAS1. (D) Essentially the same experiment as in (B), but 
SENP1 was coexpressed instead of PIAS1. 
 
5.2.1 SUMOylation influences GR target gene expression and chromatin occupancy 
In an attempt to shed light on how GR SUMOylation could influence chromatin occupancy 
and subsequently target gene expression, isogenic HEK293 cells were generated that stably 
expressed either wild-type GR (wtGR; wtGR-HEK293 cells) or the SUMOylation-defective 
GR (GR3KR; GR3KR-HEK293 cells). In GR3KR, the three lysines in SUMOylation consensus 
sites (Tian et al. 2002) were mutated to arginines, resulting in the creation of SUMOylation-
defective GR (Supplementary Fig. S1B in II). Interestingly, genome-wide GR ChIP-seq 
analyses indicated that SUMOylation influenced GR binding in a gene-specific manner (Fig. 
3, 6 and 8 in II). There were three types of GRBs; those that were insensitive, those that were 
enhanced, and those attenuated by SUMOylation sites. At many loci differences between 
wtGR and GR3KR chromatin occupancy correlated with differential expression of target 
genes (Fig. 1 and Fig. 6 in II). The most significantly influenced genes and gene programs 
due to GR SUMOylation were associated with cellular growth and survival (Fig. 1C in II); 
wtGR preferentially regulated genes with anti-proliferative properties, whereas GR3KR-
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prefered genes promoted proliferation (Fig. 1D and 6 in II). This difference was manifested 
at the cellular level, as the GR3KR-HEK293 cells proliferated significantly faster than wtGR-
HEK293 cells (Fig. 2 in II). Furthermore, the anti-proliferative affect of dex was attenuated 
in the GR3KR-HEK293 cells. Interestingly, a similar difference in the proliferation between 
wild-type and SUMOylation-defective PR has been reported to be present in breast cancer 
cells (Knutson et al. 2012).  
Morever, SUMOylation of other DNA-binding TFs has a similar effect on genes and 
gene programs involved in cellular growth and survival. Interestingly, some melanomas 
and renal cell carcinomas harbor a germline missense substitution in the SUMO consensus 
site of microphthalmia-associated TF (MITF), which severely impairs SUMOylation of the 
MITF (Bertolotto et al. 2011). Again, this SUMOylation-defect influenced MITF target genes 
involved in cell growth, proliferation and inflammation. Interestingly, similarly to the GR, 
SUMOylation of MITF influenced occupancy of the TF and a subset of its target gene loci 
(Bertolotto et al. 2011). These results imply that SUMOylation of TFs, has an important role 
in the regulation of genes and gene programs that are involved in cellular growth and 
survival. Interestingly, both GATA-1 and FoxM1 also displayed attenuated transcriptional 
function when their SUMOylation was disrupted (Lee et al. 2009a, Schimmel et al. 2014), 
providing further evidence that SUMOylation can also enhance transcriptional activity. 
The differences in the regulation of cellular growth pathways between wild-type and 
SUMOylation-defective PR have been proposed to be a result of an altered protein-protein 
interaction between PR and its coregulators (Knutson et al. 2012). In the case of GR, motif 
enrichment analysis indicated that E-twenty-six (ETS) family proteins could at least in part 
explain the difference in the chromatin occupancy between the wtGR and the GR3KR, as 
the ETS binding motif was significantly enriched only in the sites preferential bound by 
GR3KR (Fig. 2 in II, Supplementary Fig. S7 in II). SUMOylation of the GR could influence 
protein-protein interactions between the GR and ETS factors, which might in turn either 
weaken or enhance GR chromatin binding, and subsequently alter target gene expression. 
Indeed, for example the ETS-like gene (ELK) 1 is capable of regulating the expression of 
many genes involved in cell cycle and cell migration by both activating and repressing 
transcription (Odrowaz & Sharrocks 2012, Göke et al. 2013). Interestingly, ETS family motifs 
are highly enriched also at SUMO-1 as well as SUMO-2/3 binding sites in WI38 fibroblasts 
and BCBL-1 lymphoma cells (Neyret-Kahn et al. 2013, Chang et al. 2013). Moreover, ETS 
factors, such as ETS1 (Ji et al. 2007), ELK1 (Yang et al. 2003, Witty et al. 2010), and ELK4 
(Kaikkonen et al. 2010) are known to be SUMOylated. However, less than 1% of ENCODE 
ELK4 ChIP-seq data from parental HEK293 cells (GSM935590) colocalized with the GRBs 
(data not shown), suggesting that another ETS family member is involved in the possible 
regulation of GR binding.  
One interesting question arises from the above results: Can SUMOylated GR bind to 
chromatin? In vitro analyses (EMSA) revealed a nearly complete up-shift of wtGR-GRE 
complexes in the presence of anti-SUMO-2/3 antibody (Fig. 13, lane 4 vs. 5), indicating that 
SUMO-2-modified GR was capable of avidly binding to DNA. The binding of SUMO-2/3 to 
chromatin in the wtGR-HEK293 cells resembled that of GR, with the GRE being the most 
prominently enriched sequence motif at the SUMOBs (Fig. 4C in II). This indicates that 
SUMO-2/3 and GR could occupy the same genomic region, suggesting that the SUMO-2/3-
modified GR could bind to chromatin also in vivo. Furthermore, several loci in ChIP-seq 
displayed co-occupancy of GR and SUMO-2/3 (Fig. 6 in II). Re-ChIP analyses added further 
proof for the notion that SUMO-2/3-modified GR could bind to chromatin (Fig. 7 in II). 
Similarly, SUMO-2/3-modified AR has been found to occupy chromatin (Rytinki et al. 2012). 
Moreover, the overlap between GRBs and SUMOBs was markedly weaker in the GR3KR-
HEK293 cells than in the wtGR-HEK293 cells (Fig. 5 in II). However, also the GR3KR 
displayed colocalization with SUMOBs (Fig. 5 in II), suggesting that other SUMOylated 
proteins in addition to the GR can bind to these regions. 
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Previous work has shown that SUMOylation sites that overlap with the SC motifs 
restrict the receptor activity on synthetic promoters containing multiple GREs (Le Drean et 
al. 2002, Holmstrom et al. 2003, Holmstrom et al. 2008). This present genome-wide GR 
binding data did not reveal any clear difference in the number of GRBs between the wtGR- 
and GR3KR-preferred GRBs (Fig. 3C, F-G in II). However, the better resolution available 
with newer ChIP-seq technologies, such as ChIP-exo (Rhee & Pugh 2011), could have 
provided more detailed information about the number of GREs within GRBs. 
 
 
 
Figure 13. SUMOylated GR binds to DNA in vitro. To maximize the SUMOylated pool of the GR, 
the deconjugation deficient form of SUMO-2 (SUMO-2P) was coexpressed with wtGR or GR3KR 
in COS-1 cells. EMSA analyses were performed with 32P-labeled GRE in the presence or absence 
of SUMO-2/3 (S) or control IgG (C) antibody. The arrow depicts the GR-GRE complexes, and the 
arrowhead depicts the GR-SUMO-2-GRE complexes. 
 
5.2.2 The role of GR SUMOylation in cell stress 
The secretion of glucocorticoids is regulated by the HPA axis that responds to various 
stress stimuli (Rhen & Cidlowski 2005, Silverman & Sternberg 2012, Vitale et al. 2013). Stress 
can impair the function of the immune system (Glaser & Kiecolt-Glaser 2005), and while 
glucocorticoids function as anti-inflammatory mediators during short-term stress, 
prolonged stress can transform the effect of glucocorticoids so that they become pro-
inflammatory (Sorrells & Sapolsky 2007, Sorrells et al. 2009). Interestingly, various cell stress 
conditions, including electrophilic and oxidative stress, lead to the accumulation of 
SUMOylated proteins; hyper-SUMOylation of proteins (Manza et al. 2004, Tempé et al. 2008, 
Golebiowski et al. 2009). For example, the AR is hyper-SUMOylated in prostate cancer cells 
exposed to cell stress (Rytinki et al. 2012). 
The electrophilic lipid mediator 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) that is 
derived from the cyclo-oxygenase pathway and which is capable of inducing oxidative 
stress (Kondo et al. 2001, Oeste & Pérez-Sala 2014) activates cytoprotective Keap1-nuclear 
factor erythroid 2-related factor 2 (NRF2) system (Kansanen et al. 2009, Kansanen et al. 
2012). On the other hand, 15d-PGJ2 is known to inhibit the activities of various TFs such as 
AP1 (Pérez-Sala et al. 2003), NF-κB (Cernuda-Morollón et al. 2001), and p53 (Kim et al. 2010). 
In addition, the activities of SRs, such as GR (Cheron et al. 2004, Fig. 1A-B in III), ER (Kim et 
al. 2007), and AR (Kaikkonen et al. 2013b) can be inhibited by 15d-PGJ2. Both the activation 
of NRF2 and the inhibition of TFs by 15d-PGJ2 are thought to be largely attributed to the 
reactive electrophilic α,β-unsaturated carbonyl moiety present in the cyclopentenone ring, 
through which it can form covalent adducts with thiol groups in target proteins via a 
Michael addition reaction (Oeste & Pérez-Sala 2014). Interestingly, besides forming covalent 
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adducts (Fig. 2A in III), 15d-PGJ2 induced hyper-SUMOylation of both AR and GR (Fig. 2B 
in III, Kaikkonen et al. 2013b). While the inhibitory potential of 15d-PGJ2 on AR signaling 
has been postulated to be modulated by receptor SUMOylation (Kaikkonen et al. 2013b), the 
inhibition of GR signaling was significantly SUMOylation-sensitive, on a genome-wide 
scale (Fig. 3 and Fig. 4 in III). Since GR3KR evoked a similar degree of formation of covalent 
adducts with 15d-PGJ2 as wtGR (Fig. 2A in III), the weaker inhibition of the GR3KR by the 
compound could not be due to altered adduct formation. 
Oxidative stress has also been associated with inflammation induced by the activation 
of AP1 and NF-κB (Zhou et al. 2001, Benz & Yau 2008, de Nadal et al. 2011). While the GR is 
capable of inhibiting the action of AP1 and NF-κB (Oakley & Cidlowski 2013, Fig. 6C in III), 
it can also inhibit the action of TFs involved in the regulation of oxidative stress conditions, 
such as hypoxia-inducible factor 1α (HIF1A) (Lim et al. 2014), activating TF4 (ATF4) 
(Adams 2007) (Fig. 6C in III), and NRF2 (Kratschmar et al. 2012, Fig. 1C in III). Furthermore, 
the heat shock factor 1 (HSF1) that is an essential mediator of acute stress (Åkerfelt et al. 
2010), has been reported to be inhibited by the GR (Wadekar et al. 2004). Thus, in addition 
to mediating anti-inflammatory action, GR can attenuate the properties of cell stress-
associated TFs under normal cellular conditions.  
In the oxidative stress conditions induced by 15d-PGJ2, the SUMOylation-sensitive 
inhibition of GR signaling could modulate activation of cell stress-associated TFs, such as 
HIF1A, ATF4, HSF1, and pro-inflammatory factors AP1 and NF-κB (Fig. 5C and 6C in III). 
The adaptation to cell stress occurred primarily via the change in the gene expression 
pattern through the activation of TFs inducing stress-responsive genes and the repression 
of non-essential TFs (Finkel & Holbrook 2000, Pearce & Humphrey 2001, de Nadal et al. 
2011). The repression of GR and activation of HIF1A, NRF2, AP1 and NF-κB during 
oxidative and redox stress have been previously observed (Brigelius-Flohé & Flohé 2011). 
Exposure of cells to a more general oxidative stress inducer, H2O2, also attenuated GR 
signaling (Okamoto et al. 1999, Asaba et al. 2004), inhibiting GR target gene expression in a 
SUMOylation-sensitive manner (data not shown).  
Stress in ischemia has been reported to worsen the endothelial function, which is 
reduced by the inhibition of GR signaling (Balkaya et al. 2011). Interestingly, a proteomic 
screen of SUMOylated proteins from pre- and post-ischemic brains of mice revealed hyper-
SUMOylation of GR after ischemia, suggesting that SUMOylation had attenuated the 
transcriptional activity of GR which is a protective stress response (Yang et al. 2014). These 
results along with the present data strongly suggest that cell stress-induced SUMOylation 
of the GR inhibited the activation of the receptor, ensuring the release of essential TFs that 
alleviated cell stress (Fig. 7 in III). 
NR SUMOylation has been associated with transrepression of inflammatory TFs 
(Pascual & Glass 2006, Treuter & Venteclef 2011, Venteclef et al. 2011). This type of 
transrepression mediated by peroxisome proliferator-activated receptor (PPAR) γ, liver X 
receptor (LXR), and liver receptor homolog-1 (LRH1) appears to mainly be a result of 
inhibition of corepressor clearance from promoters of NF-κB target genes (Pascual et al. 
2005, Ghisletti et al. 2007, Venteclef et al. 2010). In the case of LXR, SUMOylation can also 
mediate transrepression of STAT1 (Lee et al. 2009b). Due to the fact that GR is one of the 
most potent inhibitors of pro-inflammatory signaling, and because PTMs of GR can 
influence the transrepression of inflammatory TFs (Ito et al. 2006, Galliher-Beckley et al. 
2008, Oakley & Cidlowski 2013), it is highly possible that SUMOylation of GR plays a role 
also in the repression of the activities of the inflammatory TFs. This concept is in line with 
some preliminary analyses indicating that the SUMOylation-defective GR is more prone to 
TNFα-mediated inflammatory repression than the wtGR (data not shown). Furthermore, 
transcriptome and ChIP-seq analyses revealed differences between the wtGR and the 
GR3KR in the regulation of target genes involved in inflammatory processes, such as 
NFKBIA (Fig. 1D and 6B in II) and interleukin 8 (IL8) (Supplementary Fig. S8B and Fig. 8B 
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in II), even in the absence of inflammatory stimuli. However, more detailed analyses will be 
needed to confirm these interesting preliminary observations.  
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6 Summary and Conclusions 
Glucocorticoid signaling is essential for life as it regulates many vital biological processes, 
such as glucose metabolism and the cardiovascular system (Oakley & Cidlowski 2013, 
Kadmiel & Cidlowski 2013). Clinically, the most interesting function of glucocorticoids is 
their anti-inflammatory and -proliferative effects that are thought to mainly rely on the 
transrepression mechanisms of GR with AP1 and NF-κB (De Bosscher et al. 2003). However, 
newly published genome-wide studies are beginning to alter that concept (Uhlenhaut et al. 
2013). In recent years, SUMOylation has emerged as an important PTM, potentially 
associated with human health and disease since it is involved in a multitude of central 
cellular processes (Flotho & Melchior 2013). SUMOylation of GR was previously thought to 
simply restrict the transcriptional activity of the receptor (Tian et al. 2002). However, 
genome-wide techniques have indicated that SUMOylations do not exert a general 
repression of the TF activity. At the beginning of this thesis work, nothing was known 
about the genome-wide affects of GR SUMOylation. 
Genome-wide techniques have also revealed that NRs mainly bind to sites that are 
distal to their target gene promoters (Biddie et al. 2010), suggesting CTCF and cohesin 
ensure proper long-range interactions (Jin et al. 2013, Zuin et al. 2014). The present 
characterization of FKBP51, a sensitive biomarker of corticosteroid responsiveness, 
provided evidence that CTCF and cohesin participate in the long-range chromatin 
interactions with the GR. Furthermore, an intergenic GR super-enhancer was identified in 
chromosome 6 that may participate in the long-range chromatin regulation exerted by 
glucocorticoids. 
Moreover, this thesis work has clarified how GR SUMOylation could have an impact 
on genome-wide gene regulation. The major findings were:  
 
 Genome-wide binding of SUMO-2/3 was associated with active chromatin and 
transcription of GR target genes. 
 
 Basal GR SUMOylation influenced in the chromatin occupancy of the receptor in a 
locus-selective fashion, playing an important role in the regulation of gene and 
gene programs involved in cellular growth and survival. 
 
 Cell stress-induced hyper-SUMOylation of GR attenuated the receptor activity in 
order to ensure the activation of cell stress-associated TF, such as HIF1A, ATF4 
HSF1, AP1 and NF-κB. 
 
These results provide novel information on how GR SUMOylation influences the 
function of the GR. Two types of GR SUMOylations with different consequences on gene 
regulation were identified. Firstly, basal SUMOylation (under normal cell growth 
conditions) could modulate receptor chromatin occupancy and subsequently the regulation 
of cellular growth pathways (Fig. 14). GR SUMOylation influences both glucocorticoid up- 
and down-regulated genes, but not all GR target genes were sensitive to receptor 
SUMOylation. Secondly, cell stress-induced hyper-SUMOylation of GR attenuated the 
receptor chromatin binding and target gene expression. This attenuation ensures the 
activation of cell stress-associated TFs that are otherwise inhibited by GR (Fig. 15). In 
addition, these results were among the first to demonstrate that SUMOylated proteins 
could bind to chromatin and that they were associated with active transcription. 
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Two recent proteomic screens have identified GR as a target for both SUMO-2 and 
SUMO-3 at under normal as well as pathophysiological conditions (Schimmel et al. 2014, 
Yang et al. 2014). The discovery of hyper-SUMOylated GR from post-ischemic mouse brains 
strongly supports the concept that attenuation of GR activity is a protective response, 
ensuring the activation of essential TFs to alleviate cell stress. 
 
 
 
Figure 14. Model of the genome-wide effect of basal GR SUMOylation. While SUMOylation-
competent GR (blue) preferentially regulates the genes associated with anti-proliferation, 
SUMOylation-defective GR (red) preferentially regulated genes promoting cell growth. In 
addition to altered chromatin occupancy, the SUMOyaltion of GR is believed to influence the 
protein-protein interactions of GR with other TFs (V and P) and coregulators (v and p). These 
changes influence to the differential regulation of gene expression observed between receptor 
forms. 
 
In addition to altered chromatin occupancy between wtGR and GR3KR, SUMOylation of 
GR could alter the protein-protein interaction of the receptor. Proteomic screens for GR-
protein interactions altered by SUMOylation would be valuable for clarifying the 
underlying coregulatory-networks altered by the modification.  
 
 
 
Figure 15. Model of the genome-wide action of cell stress triggered hyper-SUMOylation of GR. 
Activated GR is able to repress (blunt arrow) the properties of cell stress-associated TFs (left 
side). 15d-PGJ2 triggers hyper-SUMOylation of GR, which results in an inhibition of GR signaling. 
This in turn leads to the activation of cell stress-associated TFs (arrow) (right side). 
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The genome-wide techniques, such as ChIP-seq are highly powerful tools that could be 
also utilized in animal model systems. Interestingly, a mouse model containing 
SUMOylation-defective SF-1 knockin has proven to represent a valuable in vivo approach to 
study NR SUMOylation (Lee et al. 2011). Since the GR SUMOylation seemed to influence 
the inflammatory responses, a knockin animal model expressing SUMOylation-defective 
GR would give information on how GR SUMOylation could modify inflammatory 
responses in a genuine mammalian organism. 
The most important functions of glucocorticoids in disease treatment are attributable to 
their anti-proliferative and -inflammatory capabilities and these are both influenced by GR 
SUMOylation. The results presented in this thesis represent novel information on GR 
signaling that will be valuable for the development of more efficient GR modulators for 
medical purposes. 
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of Glucocorticoid Signaling 
by SUMO Modifications
Glucocorticoid receptor (GR) 
is a corticosteroid-controlled 
transcription factor important in 
the mediation of anti-inflammatory 
effects. In addition to corticosteroids 
the action of GR can also be regulated 
by post-translational modifications. 
This study proves by transcriptome 
and cistrome analyses that small 
ubiquitin-related modifier (SUMO) 
regulates GR action in basal and cell 
stress conditions. The novel results 
represented will be valuable for 
future targeting of GR in health and 
disease.
